光学相干断层成像结合病理评价药物洗脱支架术后延迟的内膜修复愈合情况以及阿托伐他汀改善新生内膜愈合情况的研究
|
摘要
目的：药物洗脱支架(drug-eluting stent, DES)术后发生的晚期(late stent thrombosis,LST)和晚晚期支架内血栓(very late stent thrombosis, VLST)具有很高的死亡率和急性心肌梗死率,危害极大。和金属裸支架(bare metal stent, BMS)相比,DES术后延迟的内膜修复愈合以及不完全的再内皮化被认为和LST和VLST发生密切相关。有相关研究证实阿托伐他汀可以通过激活PI3K/Akt通路增加内皮型一氧化氮合酶(endothelial nitric oxide synthase, eNOS)和一氧化氮(nitric oxide, NO)表达增强内皮细胞功能,最近研究发现阿托伐他汀还可以促进骨髓中的内皮祖细胞(endothelia progenitor cell, EPC)的动员,而EPC是内皮细胞的前体细胞,损伤发生时,EPC可以从骨髓中动员出来并归巢到血管内膜损伤处,通过增殖分化为成熟内皮细胞修复损伤。因此本课题利用中华小型猪BMS和DES支架植入模型,通过活体光学相干断层成像技术(optical coherence tomography, OCT)检查评价支架处内膜覆盖情况,对比病理中的内膜修复和再内皮化情况,评价DES术后内膜延迟愈合的情况,并给予阿托伐他汀进行干预治疗,观察阿托伐他汀对DES术后内膜和内皮修复的影响,并探讨其机制。
方法：健康中华小型猪随机分为BMS组(n=15),DES组(n=15),DES+阿托伐他汀组(n=15)。每组又分为7天组,14天组和28天组三个亚组(n=5/亚组)。DES+阿托伐他汀组术前给予50mg阿托伐他汀,术后改为20mg/天。通过OCT评价支架植入即刻、7天、14天、28天的支架覆盖率、新生内膜厚度、新生内膜面积等指标,并和病理结果进行比较。术后7天、14天、28天通过免疫组化和扫描电镜评价支架处再内皮化情况、血小板粘附聚集和eNOS表达情况。通过流式细胞仪检测支架植入术前和支架术后7天、14天、28天外周血单个核细胞中的EPC比例。
结果：OCT发现DES组内膜修复愈合较BMS组明显减慢,7天(56.8±5.7%vs44.4±1.0%,P<0.05)和14天(45.3±2.8%vs20.3±3.3%,P<0.05)时支架未覆盖率明显增高,DES+阿托伐他汀组术后7天(42.7±1.3%)和14天(24.8±4.3%)时支架未覆盖率明显降低,但28天时三组支架内膜均基本完全覆盖,覆盖率没有差异。OCT和病理检查测得的内膜覆盖率和扫描电镜检测的内皮覆盖率存在明显差异(P<0.05),再内皮化情况要明显延迟于内膜覆盖情况,尤其是在DES组差异更加明显。而DES+阿托伐他汀组再内皮化情况明显改善,内皮覆盖率较DES组明显增加,即使是在28天各组内膜化基本完全时,三组内皮覆盖率仍有明显差异(BMS组97.0±4.0%,SES组54.4±13.0%,SES+阿托伐他汀组77.3±10.3%)。流式细胞仪检测发现SES+阿托伐他汀组外周血EPC增加(0.21±0.02%vs0.11+0.03%,P=0.022),免疫组化染色发现支架上覆盖内皮细胞表达eNOS增加,扫描电镜结果提示单位面积内皮细胞上粘附的血小板数目也减少。
结论：DES术后内膜修复和再内皮化并不同步,再内皮化更加延迟,阿托伐他汀可以促进DES术后内膜修复和内皮覆盖,并改善支架处新生内皮功能,其机制可能和促进骨髓EPC动员以及激活内皮细胞eNOS有关,这些可能有助于降低LST发生风险。
目的：药物洗脱支架(drug-eluting stent, DES)术后发生的晚期支架内血栓(late stent thrombosis, LST)具有很高的死亡率和心梗率,危害极大,其机制主要认为和DES术后内膜修复愈合延迟,支架长期裸露有关,而过早的停用阿司匹林和氯吡格雷的双联抗血小板治疗可以明显增加LST的发生风险。但临床实践中阿司匹林可以导致胃溃疡和出血,有时植入DES后的患者不能耐受,需停用阿司匹林改为单纯服用氯吡格雷进行抗血小板治疗,这一经验性抗血小板治疗的效果尚无研究考证。在前期动物实验中,我们已经通过光学相干断层成像(optical coherence tomography, OCT)和病理检查证实阿托伐他汀可以改善DES术后延迟的内膜修复和促进再内皮化,囚此,本研究试图通过小型猪动物模型评价单纯服用氯吡格雷在内膜尚未完全修复的药物洗脱支架中的安全性,以及观察阿托伐他汀改善的内膜和内皮修复是否能够减低支架内血栓的发生。
方法：18头中华小型猪(25+5kg)随机分为3组：BMS组(n=6),SES组(n=6),SES+阿托伐他汀组(n=6)。各组均在术前一晚给予300mg阿司匹林和300mg氯吡格雷,然后进行支架植入,BMS组植入无药物涂层的Firebird-2金属裸支架,SES组和SES+阿托伐他汀组植入携带西罗莫司的Firebird-2支架,术后改为100mg阿司匹林和75mg氯吡格雷治疗,持续一周,然后停用阿司匹林,仅给予氯毗格雷治疗。支架术后和14天、21天、28天进行冠脉造影和OCT检查,评价内膜修复情况和支架内血栓发生情况,同时抽取外周血进行光学比浊法检查血小板聚集率。对发生血栓的动物处死行病理检查,并通过扫描电镜评价血小板粘附情况。
结果：术后28天各组累计支架内血栓发生率分别为BMS组0%(0/6),SES组16.7%(1/6),SES+阿托伐他汀组33.3%(2/6),但SES组和SES+阿托伐他汀组血栓发生率并无差异(P=1.0)。14天时支架新生内膜覆盖率BMS组(77.3±8.0%)和SES+阿托伐他汀组(75.2±9.5%)要优于SES组(54.7±6.2%,P<0.001),但21天和28天时,三组间支架覆盖率并无差异。病理检查发现支架内血栓基本均发生在支架裸露部位,扫描电镜检测各组血小板计数分别为BMS组9.7±1.8,SES组21.9±3.9,SES+阿托伐他汀组18.0±3.5,SES组和SES+阿托伐他汀组单位面积内皮细胞粘附血小板数目要高于BMS组(SES vs BMS, P=0.014;SES+阿托伐他汀vs BMS, P=0.052)。
结论：在小型猪支架模型中,DES术后支架内膜尚未完全修复愈合时,单独氯吡格雷抗血小板治疗不能完全阻止小型猪支架模型中的血栓形成,其支架内血栓的发生机制可能与裸露的支架丝以及损伤的内皮功能有关。而阿托伐他汀虽然可以改善DES术后早期内膜修复,但并未减少支架内血栓的发生。
目的：药物洗脱支架(drug-eluting stent, DES)术后延迟的内膜修复愈合情况被认为和晚期支架内血栓(late stent thrombosis, LST)的发生密切相关。光学相干断层成像技术(optical coherence tomography, OCT)是近年来新兴的冠脉内成像技术,具有10um的超高分辨率,可以准确评价DES术后的新生内膜覆盖情况。既往研究主要关注DES植入后6月以后以及更长期的内膜覆盖情况,DES术后极早期的内膜修复愈合情况尚未见报道。近年来研究显示新一代药物洗脱支架依维莫司洗脱支架(everolimus-eluting stent, EES)同原来的西罗莫司洗脱支架(sirolimus-eluting stent,SES)相比能够进一步减少MACE事件和LST的发生,但尚无对比EES和SES对极早期内膜修复愈合影响的研究。因此,本研究通过OCT评价DES术后7天以及3个月左右的新生内膜修复情况,了解DES术后内膜修复愈合规律,并探讨可能影响早期内膜修复愈合的因素。
方法：回顾性分析了2009年9月至2011年9月间,37名存在冠心病多支病变的患者,这些患者均接受了分次DES植入,并在支架植入即刻和随访中接受OCT检查。根据第二次OCT检查时间分为7天组(n=18例,36DES)和3月组(n=19例,33DES)。利用OCT专用分析软件(QIVUS2.1Bate Version with OCT Module)检测术后即刻和随访中的支架覆盖率、贴壁不良率、管腔面积、支架面积、附壁血栓发生率、新生内膜厚度等指标。并根据患者临床表现和植入支架类型不同进行多元线性回归分析,观察各因素对支架新生内膜覆盖率和支架贴壁不良率的影响。
结果：7天时18.7±16.6%的支架丝已被覆盖,3月时77.3±16.0%的支架丝已被覆盖。多元线性回归分析发现SES(p系数-14.9%,95%可信区间：-23.2%～-6.6%,P=0.001)和高血压(p系数-9.3%,95%可信区间：-17.4%～-1.3%,P=0.025)两个因素和支架内膜覆盖率负相关,3月时植入EES患者覆盖率85.6±5.9%,而植入SES组仅有69.8±3.7%(P=0.003)；高血压患者组平均覆盖率64.5±4.2%,非高血压组80.9±4.2%(P=0.02)。在支架贴壁不良方面,回归分析发现术后即刻贴壁不良(p系数0.3%,95%可信区间：0.1%～0.5%,P=0.002)和慢性完全闭塞病变(chronic total occlusion, CTO)(β系数1.3%,95%可信区间：0.2%～2.4%,P=0.018)能够影响支架植入术后3月的贴壁不良率。
结论：DES植入术后一周即检测到支架处新生内膜覆盖,但覆盖率较低,大部分支架丝裸露。在术后极早期的内膜修复方面,新一代的EES和SES相比支架新生内膜覆盖率更高,高血压患者和非高血压患者相比术后3月内的支架新生内膜覆盖率下降。而术后即刻支架贴壁不良和CTO病变可能会增加术后早期的随访支架贴壁不良。
Background:Delayed neointimal coverage and re-endothelialization after drug-eluting stent implantation are thought to be the underlying mechanisms of late stent thrombosis (LST).
Methods and Results:Forty-five Chinese minipigs were divided into three groups (n=15each):bare metal stent (BMS), SES, and SES and atorvastatin treatment (SES+ator). Neointimal coverage and endothelium coverage were evaluated separately by optical coherence tomography (OCT), pathology, and scanning electron microscopy (SEM) at days7,14and28. OCT showed that SES significantly delayed neointimal coverage compared with BMS and the percentage of uncovered struts in the SES+ator group was significantly decreased on days7(42.7±1.3%vs56.8±5.7%, P<0.01) and14(24.8±4.3%vs45.3±2.8%, P<0.01) compared with the SES group. However, re-endothelialization was even more seriously delayed than the neointima formation after SES deployed (P<0.05). Pathology and SEM revealed improved re-endothelialization on the neointima by atorvastatin therapy in terms of more struts covered by endothelium, less platelet adhesion, and higher eNOS expression of the endothelial cells in the SES+ator group. Flow cytometry illustrated that the SES+ator group had more mobilized EPCs compared with the SES group at day7(0.21+0.02%vs0.11±0.03%, P=0.022).
Conclusions:Atorvastatin pretreatment can accelerate both neointimal coverage and re-endothelialization after SES implantation which may be mediated by the mobilization of EPC and enhancement of the endothelial function of the neointima.
Objective:To investigate whether monotherapy by clopidogrel without aspirin after drug-eluting stent implantation (DES) was effective to inhibite platelets activation and prevent stent thrombosis formation.
Methods:Eighteen Chinese mini-porcine were randomized into3groups of bare metal stent (BMS)(n=6), sirolimus-eluting stent (SES)(control; n=6), and SES plus Ator group(atorvastatin; n=6). Each animal accepted300mg aspirine and300mg clopidogrel before stent implantation and100mg aspirin and75mg clopidogrel per day for7days after stent implantation. Then aspirine therapy was stopped and only75mg clopidogrel was given. Inhabitation of platelet was evaluated by platelet affregation test before PCI and at7days,14days,21days, and28days after PCI. The rate of stent thrombosis was observed by coronary angiography and optical coherence tomography (OCT). Stent thrombosis was then confirmed by pathology and the adhension of platelets on stents was evaluated by scanning electron microscopy (SEM).
Results:The percentage of stent thrombosis was0%in the BMS group (0/6),16.7%in the SES group (1/6),33.3%in the SES+ator group (2/6), respectively. Although the BMS group and the SES+ator group showed better neointima coverage compared with the SES group at14days after PCI, there was no signigicant difference about the rate of stent thrombosis between the SES group and the SES+ator group (P=1.0). the percentage of stent coverage was77.3±8.0%,54.7±6.2%, and75.2±9.5%in the BMS, SES, and SES+ator group respectively. The result of pathology showed that the stent thrombosis was mainly formed on the stent struts without neointimal coverage. SEM revealed that the number of platelet adhension was9.7±9.7,21.9±17.9and18.0±20.9in the three groups respectively. The SES group and the SES+ator group had more platelets adhension than the BMS group at28days(P=0.014and P=0.052). there was no significant difference between the SES and the SES+ator group (P=0.41).
Conclusion:mono antiplatelet therapy by clopigrel could not completely prevent stent thrombosis formation after DES implantation. although acceralted neointimal coverage was observed by atorvastatin therapy, no decrease of stent thrombosis was shown.
Objective:To evaluate the neointimal coverage at the very early phase after sirolimus-(SES) and everolimus-eluting stent (EES) implantation using optical coherence tomography (OCT).
Background:Previous studies usually focus on the delayed neointimal coverage at long term follow-up after drug-eluting stent (DES) implantation. The very early neointimal hyperplasia is seldom studied.
Methods:Thirty-seven multi-vessel coronary artery disease patients who accepted OCT examination both at immediately post-intervention and follow-up were classified into either the7-day group (n=18patients,36stents) or the3-month group (n=19patients,33stents). The stent coverage and malapposition was analyzed using OCT.
Results:18.7±16.6%and77.3±16.0%of the struts were covered at7days and3months, respectively. SES and hypertension were associated with a significantly lower percentage of stent coverage at3months (69.8±3.7%in SES vs85.6±5.9%in EES, P=0.003;64.5±4.2%vs80.9±4.2%, P=0.02, respectively). The stepwise linear regression analyses showed that the percentage of immediately malapposed struts (beta coefficient:0.3%,95%confidence interval:0.1%to0.5%, P=0.002) and chronic total occlusion (CTO)(beta coefficient:1.3%,95%confidence interval:0.2%to2.4%, P=0.018) could increase the percentage of struts malapposition in the3months follow-up.
Conclusion:Neointimal coverage could be detected at one week after DES implantation by OCT. However, EES showed better neointimal coverage compared with SES. Hypertension could impact the neointimal coverage in the first3months. The rate of stent malapposition immediately after intervention and CTO may increase struts malapposition in the very early phase after DES implantation.
方法：健康中华小型猪随机分为BMS组(n=15),DES组(n=15),DES+阿托伐他汀组(n=15)。每组又分为7天组,14天组和28天组三个亚组(n=5/亚组)。DES+阿托伐他汀组术前给予50mg阿托伐他汀,术后改为20mg/天。通过OCT评价支架植入即刻、7天、14天、28天的支架覆盖率、新生内膜厚度、新生内膜面积等指标,并和病理结果进行比较。术后7天、14天、28天通过免疫组化和扫描电镜评价支架处再内皮化情况、血小板粘附聚集和eNOS表达情况。通过流式细胞仪检测支架植入术前和支架术后7天、14天、28天外周血单个核细胞中的EPC比例。
结果：OCT发现DES组内膜修复愈合较BMS组明显减慢,7天(56.8±5.7%vs44.4±1.0%,P<0.05)和14天(45.3±2.8%vs20.3±3.3%,P<0.05)时支架未覆盖率明显增高,DES+阿托伐他汀组术后7天(42.7±1.3%)和14天(24.8±4.3%)时支架未覆盖率明显降低,但28天时三组支架内膜均基本完全覆盖,覆盖率没有差异。OCT和病理检查测得的内膜覆盖率和扫描电镜检测的内皮覆盖率存在明显差异(P<0.05),再内皮化情况要明显延迟于内膜覆盖情况,尤其是在DES组差异更加明显。而DES+阿托伐他汀组再内皮化情况明显改善,内皮覆盖率较DES组明显增加,即使是在28天各组内膜化基本完全时,三组内皮覆盖率仍有明显差异(BMS组97.0±4.0%,SES组54.4±13.0%,SES+阿托伐他汀组77.3±10.3%)。流式细胞仪检测发现SES+阿托伐他汀组外周血EPC增加(0.21±0.02%vs0.11+0.03%,P=0.022),免疫组化染色发现支架上覆盖内皮细胞表达eNOS增加,扫描电镜结果提示单位面积内皮细胞上粘附的血小板数目也减少。
结论：DES术后内膜修复和再内皮化并不同步,再内皮化更加延迟,阿托伐他汀可以促进DES术后内膜修复和内皮覆盖,并改善支架处新生内皮功能,其机制可能和促进骨髓EPC动员以及激活内皮细胞eNOS有关,这些可能有助于降低LST发生风险。
目的：药物洗脱支架(drug-eluting stent, DES)术后发生的晚期支架内血栓(late stent thrombosis, LST)具有很高的死亡率和心梗率,危害极大,其机制主要认为和DES术后内膜修复愈合延迟,支架长期裸露有关,而过早的停用阿司匹林和氯吡格雷的双联抗血小板治疗可以明显增加LST的发生风险。但临床实践中阿司匹林可以导致胃溃疡和出血,有时植入DES后的患者不能耐受,需停用阿司匹林改为单纯服用氯吡格雷进行抗血小板治疗,这一经验性抗血小板治疗的效果尚无研究考证。在前期动物实验中,我们已经通过光学相干断层成像(optical coherence tomography, OCT)和病理检查证实阿托伐他汀可以改善DES术后延迟的内膜修复和促进再内皮化,囚此,本研究试图通过小型猪动物模型评价单纯服用氯吡格雷在内膜尚未完全修复的药物洗脱支架中的安全性,以及观察阿托伐他汀改善的内膜和内皮修复是否能够减低支架内血栓的发生。
方法：18头中华小型猪(25+5kg)随机分为3组：BMS组(n=6),SES组(n=6),SES+阿托伐他汀组(n=6)。各组均在术前一晚给予300mg阿司匹林和300mg氯吡格雷,然后进行支架植入,BMS组植入无药物涂层的Firebird-2金属裸支架,SES组和SES+阿托伐他汀组植入携带西罗莫司的Firebird-2支架,术后改为100mg阿司匹林和75mg氯吡格雷治疗,持续一周,然后停用阿司匹林,仅给予氯毗格雷治疗。支架术后和14天、21天、28天进行冠脉造影和OCT检查,评价内膜修复情况和支架内血栓发生情况,同时抽取外周血进行光学比浊法检查血小板聚集率。对发生血栓的动物处死行病理检查,并通过扫描电镜评价血小板粘附情况。
结果：术后28天各组累计支架内血栓发生率分别为BMS组0%(0/6),SES组16.7%(1/6),SES+阿托伐他汀组33.3%(2/6),但SES组和SES+阿托伐他汀组血栓发生率并无差异(P=1.0)。14天时支架新生内膜覆盖率BMS组(77.3±8.0%)和SES+阿托伐他汀组(75.2±9.5%)要优于SES组(54.7±6.2%,P<0.001),但21天和28天时,三组间支架覆盖率并无差异。病理检查发现支架内血栓基本均发生在支架裸露部位,扫描电镜检测各组血小板计数分别为BMS组9.7±1.8,SES组21.9±3.9,SES+阿托伐他汀组18.0±3.5,SES组和SES+阿托伐他汀组单位面积内皮细胞粘附血小板数目要高于BMS组(SES vs BMS, P=0.014;SES+阿托伐他汀vs BMS, P=0.052)。
结论：在小型猪支架模型中,DES术后支架内膜尚未完全修复愈合时,单独氯吡格雷抗血小板治疗不能完全阻止小型猪支架模型中的血栓形成,其支架内血栓的发生机制可能与裸露的支架丝以及损伤的内皮功能有关。而阿托伐他汀虽然可以改善DES术后早期内膜修复,但并未减少支架内血栓的发生。
目的：药物洗脱支架(drug-eluting stent, DES)术后延迟的内膜修复愈合情况被认为和晚期支架内血栓(late stent thrombosis, LST)的发生密切相关。光学相干断层成像技术(optical coherence tomography, OCT)是近年来新兴的冠脉内成像技术,具有10um的超高分辨率,可以准确评价DES术后的新生内膜覆盖情况。既往研究主要关注DES植入后6月以后以及更长期的内膜覆盖情况,DES术后极早期的内膜修复愈合情况尚未见报道。近年来研究显示新一代药物洗脱支架依维莫司洗脱支架(everolimus-eluting stent, EES)同原来的西罗莫司洗脱支架(sirolimus-eluting stent,SES)相比能够进一步减少MACE事件和LST的发生,但尚无对比EES和SES对极早期内膜修复愈合影响的研究。因此,本研究通过OCT评价DES术后7天以及3个月左右的新生内膜修复情况,了解DES术后内膜修复愈合规律,并探讨可能影响早期内膜修复愈合的因素。
方法：回顾性分析了2009年9月至2011年9月间,37名存在冠心病多支病变的患者,这些患者均接受了分次DES植入,并在支架植入即刻和随访中接受OCT检查。根据第二次OCT检查时间分为7天组(n=18例,36DES)和3月组(n=19例,33DES)。利用OCT专用分析软件(QIVUS2.1Bate Version with OCT Module)检测术后即刻和随访中的支架覆盖率、贴壁不良率、管腔面积、支架面积、附壁血栓发生率、新生内膜厚度等指标。并根据患者临床表现和植入支架类型不同进行多元线性回归分析,观察各因素对支架新生内膜覆盖率和支架贴壁不良率的影响。
结果：7天时18.7±16.6%的支架丝已被覆盖,3月时77.3±16.0%的支架丝已被覆盖。多元线性回归分析发现SES(p系数-14.9%,95%可信区间：-23.2%～-6.6%,P=0.001)和高血压(p系数-9.3%,95%可信区间：-17.4%～-1.3%,P=0.025)两个因素和支架内膜覆盖率负相关,3月时植入EES患者覆盖率85.6±5.9%,而植入SES组仅有69.8±3.7%(P=0.003)；高血压患者组平均覆盖率64.5±4.2%,非高血压组80.9±4.2%(P=0.02)。在支架贴壁不良方面,回归分析发现术后即刻贴壁不良(p系数0.3%,95%可信区间：0.1%～0.5%,P=0.002)和慢性完全闭塞病变(chronic total occlusion, CTO)(β系数1.3%,95%可信区间：0.2%～2.4%,P=0.018)能够影响支架植入术后3月的贴壁不良率。
结论：DES植入术后一周即检测到支架处新生内膜覆盖,但覆盖率较低,大部分支架丝裸露。在术后极早期的内膜修复方面,新一代的EES和SES相比支架新生内膜覆盖率更高,高血压患者和非高血压患者相比术后3月内的支架新生内膜覆盖率下降。而术后即刻支架贴壁不良和CTO病变可能会增加术后早期的随访支架贴壁不良。
Background:Delayed neointimal coverage and re-endothelialization after drug-eluting stent implantation are thought to be the underlying mechanisms of late stent thrombosis (LST).
Methods and Results:Forty-five Chinese minipigs were divided into three groups (n=15each):bare metal stent (BMS), SES, and SES and atorvastatin treatment (SES+ator). Neointimal coverage and endothelium coverage were evaluated separately by optical coherence tomography (OCT), pathology, and scanning electron microscopy (SEM) at days7,14and28. OCT showed that SES significantly delayed neointimal coverage compared with BMS and the percentage of uncovered struts in the SES+ator group was significantly decreased on days7(42.7±1.3%vs56.8±5.7%, P<0.01) and14(24.8±4.3%vs45.3±2.8%, P<0.01) compared with the SES group. However, re-endothelialization was even more seriously delayed than the neointima formation after SES deployed (P<0.05). Pathology and SEM revealed improved re-endothelialization on the neointima by atorvastatin therapy in terms of more struts covered by endothelium, less platelet adhesion, and higher eNOS expression of the endothelial cells in the SES+ator group. Flow cytometry illustrated that the SES+ator group had more mobilized EPCs compared with the SES group at day7(0.21+0.02%vs0.11±0.03%, P=0.022).
Conclusions:Atorvastatin pretreatment can accelerate both neointimal coverage and re-endothelialization after SES implantation which may be mediated by the mobilization of EPC and enhancement of the endothelial function of the neointima.
Objective:To investigate whether monotherapy by clopidogrel without aspirin after drug-eluting stent implantation (DES) was effective to inhibite platelets activation and prevent stent thrombosis formation.
Methods:Eighteen Chinese mini-porcine were randomized into3groups of bare metal stent (BMS)(n=6), sirolimus-eluting stent (SES)(control; n=6), and SES plus Ator group(atorvastatin; n=6). Each animal accepted300mg aspirine and300mg clopidogrel before stent implantation and100mg aspirin and75mg clopidogrel per day for7days after stent implantation. Then aspirine therapy was stopped and only75mg clopidogrel was given. Inhabitation of platelet was evaluated by platelet affregation test before PCI and at7days,14days,21days, and28days after PCI. The rate of stent thrombosis was observed by coronary angiography and optical coherence tomography (OCT). Stent thrombosis was then confirmed by pathology and the adhension of platelets on stents was evaluated by scanning electron microscopy (SEM).
Results:The percentage of stent thrombosis was0%in the BMS group (0/6),16.7%in the SES group (1/6),33.3%in the SES+ator group (2/6), respectively. Although the BMS group and the SES+ator group showed better neointima coverage compared with the SES group at14days after PCI, there was no signigicant difference about the rate of stent thrombosis between the SES group and the SES+ator group (P=1.0). the percentage of stent coverage was77.3±8.0%,54.7±6.2%, and75.2±9.5%in the BMS, SES, and SES+ator group respectively. The result of pathology showed that the stent thrombosis was mainly formed on the stent struts without neointimal coverage. SEM revealed that the number of platelet adhension was9.7±9.7,21.9±17.9and18.0±20.9in the three groups respectively. The SES group and the SES+ator group had more platelets adhension than the BMS group at28days(P=0.014and P=0.052). there was no significant difference between the SES and the SES+ator group (P=0.41).
Conclusion:mono antiplatelet therapy by clopigrel could not completely prevent stent thrombosis formation after DES implantation. although acceralted neointimal coverage was observed by atorvastatin therapy, no decrease of stent thrombosis was shown.
Objective:To evaluate the neointimal coverage at the very early phase after sirolimus-(SES) and everolimus-eluting stent (EES) implantation using optical coherence tomography (OCT).
Background:Previous studies usually focus on the delayed neointimal coverage at long term follow-up after drug-eluting stent (DES) implantation. The very early neointimal hyperplasia is seldom studied.
Methods:Thirty-seven multi-vessel coronary artery disease patients who accepted OCT examination both at immediately post-intervention and follow-up were classified into either the7-day group (n=18patients,36stents) or the3-month group (n=19patients,33stents). The stent coverage and malapposition was analyzed using OCT.
Results:18.7±16.6%and77.3±16.0%of the struts were covered at7days and3months, respectively. SES and hypertension were associated with a significantly lower percentage of stent coverage at3months (69.8±3.7%in SES vs85.6±5.9%in EES, P=0.003;64.5±4.2%vs80.9±4.2%, P=0.02, respectively). The stepwise linear regression analyses showed that the percentage of immediately malapposed struts (beta coefficient:0.3%,95%confidence interval:0.1%to0.5%, P=0.002) and chronic total occlusion (CTO)(beta coefficient:1.3%,95%confidence interval:0.2%to2.4%, P=0.018) could increase the percentage of struts malapposition in the3months follow-up.
Conclusion:Neointimal coverage could be detected at one week after DES implantation by OCT. However, EES showed better neointimal coverage compared with SES. Hypertension could impact the neointimal coverage in the first3months. The rate of stent malapposition immediately after intervention and CTO may increase struts malapposition in the very early phase after DES implantation.
引文
1. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans:Delayed healing and late thrombotic risk. J Am Coll Cardiol.2006;48:193-202
2. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice.4-year results from a large 2-institutional cohort study. J Am Coll Cardiol.2008;52:1134-1140
3. Trabattoni D, Fabbiocchi F, Montorsi P, Ravagnani P, Galli S, Teruzzi G, Calligaris G, De Martini S, Bartorelli AL. Stent thrombosis after sirolimus- and paclitaxel-eluting stent implantation in daily clinical practice:Analysis of a single center registry. Catheter Cardiovasc Interv.2007;70:415-421
4. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents:A cause for concern. Circulation. 2007;115:1440-1455; discussion 1455
5. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis:Strut coverage as a marker of endothelialization. Circulation.2007; 115:2435-2441
6. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents:An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584-2591
7. Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, Feres F, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation.2003;107:381-383
8. Prati F, Zimarino M, Stabile E, Pizzicannella G, Fouad T, Rabozzi R, Filippini A, Pizzicannella J, Cera M, De Caterina R. Does optical coherence tomography identify arterial healing after stenting? An in vivo comparison with histology, in a rabbit carotid model. Heart.2008;94:217-221
9. Suzuki Y, Ikeno F, Koizumi T, Tio F, Yeung AC, Yock PG, Fitzgerald PJ, Fearon WF. In vivo comparison between optical coherence tomography and intravascular ultrasound for detecting small degrees of in-stent neointima after stent implantation. JACC Cardiovasc Interv.2008;1:168-173
10. Ong AT, Aoki J, Kutryk MJ, Serruys PW. How to accelerate the endothelialization of stents. Arch Mal Coeur Vaiss.2005;98:123-126
11. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science.1997;275:964-967
12. Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, Oh BH, Lee MM, Park YB. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol. 2004;24:288-293
13. Banerjee S, Brilakis E, Zhang S, Roesle M, Lindsey J, Philips B, Blewett CG, Terada LS. Endothelial progenitor cell mobilization after percutaneous coronary intervention. Atherosclerosis.2006; 189:70-75
14. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:E1-7
15. Matsuo Y, Imanishi T, Hayashi Y, Tomobuchi Y, Kubo T, Hano T, Akasaka T. The effect of senescence of endothelial progenitor cells on in-stent restenosis in patients undergoing coronary stenting. Intern Med.2006;45:581-587
16. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, Grunwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (topcare-ami). Circulation.2002;106:3009-3017
17. Schachinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, Abolmaali ND, Vogl TJ, Hofmann WK, Martin H, Dimmeler S, Zeiher AM. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction:Final one-year results of the topcare-ami trial. J Am Coll Cardiol.2004;44:1690-1699
18. Kawamoto A, Asahara T, Losordo DW. Transplantation of endothelial progenitor cells for therapeutic neovascularization. Cardiovasc Radiat Med.2002;3:221-225
19. Spadaccio C, Pollari F, Casacalenda A, Alfano G, Genovese J, Covino E, Chello M. Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery:A randomized control study. J Cardiovasc Pharmacol.2010;55:30-38
20. Xu J, Liu X, Chen J, Zacharek A, Cui X, Savant-Bhonsale S, Liu Z, Chopp M. Simvastatin enhances bone marrow stromal cell differentiation into endothelial cells via notch signaling pathway. Am J Physiol Cell Physiol.2009;296:C535-543
21. Suzuki G, Iyer V, Cimato T, Canty JM, Jr. Pravastatin improves function in hibernating myocardium by mobilizing cd133+ and ckit+ bone marrow progenitor cells and promoting myocytes to reenter the growth phase of the cardiac cell cycle. Circ Res.2009; 104:255-264,210p following 264
22. Hristov M, Fach C, Becker C, Heussen N, Liehn EA, Blindt R, Hanrath P, Weber C. Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. Atherosclerosis.2007;192:413-420
23. Kuwana M, Okazaki Y, Kaburaki J. Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod Rheumatol. 2009;19:530-535
24. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med.2002;346:1773-1780
25. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med.2003;349:1315-1323
26. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA.2005;293:2126-2130
27. Fukuda D, Enomoto S, Shirakawa I, Nagai R, Sata M. Fluvastatin accelerates re-endothelialization impaired by local sirolimus treatment. Eur J Pharmacol. 2009;612:87-92
28. Hibbert B, Ma X, Pourdjabbar A, Simard T, Rayner K, Sun J, Chen YX, Filion L, O'Brien ER. Pre-procedural atorvastatin mobilizes endothelial progenitor cells: Clues to the salutary effects of statins on healing of stented human arteries. PLoS One.2011;6:e16413
29. Hong SJ, Choi SC, Kim JS, Shim WJ, Park SM, Ahn CM, Park JH, Kim YH, Lim DS. Low-dose versus moderate-dose atorvastatin after acute myocardial infarction:8-month effects on coronary flow reserve and angiogenic cell mobilisation. Heart.2010;96:756-764
30. Cho JS, Jeong MH, Sim DS, Hong YJ, Lim KS, Kim JH, Kim HD, Baek JY, Yoon HJ, Her SH, Jin SW, Ahn Y, Cho JG, Park JC, Kang JC. Effects of combined therapy with ezetimibe plus simvastatin after drug-eluting stent implantation in a porcine coronary restenosis model. J Korean Med Sci. 2009;25:716-722
31. Bezerra HG, Costa MA, Guagliumi G, Rollins AM, Simon DI. Intracoronary optical coherence tomography:A comprehensive review clinical and research applications. JACC Cardiovasc Interv.2009;2:1035-1046
32. Prati F, Regar E, Mintz GS, Arbustini E, Di Mario C, Jang IK, Akasaka T, Costa M, Guagliumi G, Grube E, Ozaki Y, Pinto F, Serruys PW. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography:Physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J.2010;31:401-415
33. Kim JS, Fan C, Choi D, Jang IK, Lee JM, Kim TH, Park SM, Paik SI, Ko YG, Hong MK, Jang Y, Chung N. Different patterns of neointimal coverage between acute coronary syndrome and stable angina after various types of drug-eluting stents implantation; 9-month follow-up optical coherence tomography study. Int J Cardiol.2009
34. Katoh H, Shite J, Shinke T, Matsumoto D, Tanino Y, Ogasawara D, Sawada T, Miyoshi N, Kawamori H, Yoshino N, Hirata K. Delayed neointimalization on sirolimus-eluting stents:6-month and 12-month follow up by optical coherence tomography. Circ J.2009;73:1033-1037
35. Kim TH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK. Long-term (>/=2 years) follow-up optical coherence tomographic study after sirolimus-and paclitaxel-eluting stent implantation:Comparison to 9-month follow-up results. Int J Cardiovasc Imaging.2010;27:875-881
36. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada T, Paredes OL, Hirata K, Yokoyama M. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up:Evaluated by optical coherence tomography. Eur Heart J.2007;28:961-967
37. Kim JS, Kim TH, Fan C, Lee JM, Kim W, Ko YG, Choi D, Hong MK, Jang Y. Comparison of neointimal coverage of sirolimus-eluting stents and paclitaxel-eluting stents using optical coherence tomography at 9 months after implantation. Circ J.2009;74:320-326
38. Hanna NN, Gaglia MA, Jr., Torguson R, Ben-Dor I, Gonzalez MA, Collins SD, Syed AI, Maluenda G, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R. Three-year outcomes following sirolimus-versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the rewards registry). Am J Cardiol.2010; 106:504-510
39. Choi HH, Kim JS, Yoon DH, Hong KS, Kim TH, Kim BK, Ko YG, Choi D, Jang Y, Hong MK. Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation:Comparison with sirolimus-eluting stent using optical coherence tomography. Int J Cardiovasc Imaging.2011
40. Smith SC, Jr., Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. Aha/acc guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease:2006 update: Endorsed by the national heart, lung, and blood institute. Circulation. 2006;113:2363-2372
41. Jaschke B, Michaelis C, Milz S, Vogeser M, Mund T, Hengst L, Kastrati A, Schomig A, Wessely R. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res.2005;68:483-492
42. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents:Are human and animal studies comparable? Heart.2003;89:133-138
43. Kong D, Melo LG, Mangi AA, Zhang L, Lopez-Ilasaca M, Perrella MA, Liew CC, Pratt RE, Dzau VJ. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation.2004; 109:1769-1775
44. Moreno PR, Sanz J, Fuster V. Promoting mechanisms of vascular health: Circulating progenitor cells, angiogenesis, and reverse cholesterol transport. J Am Coll Cardiol.2009;53:2315-2323
45. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, Dimmeler S. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation.2001;103:2885-2890
46. Ishigami K, Uemura S, Morikawa Y, Soeda T, Okayama S, Nishida T, Takemoto Y, Onoue K, Somekawa S, Takeda Y, Kawata H, Horii M, Saito Y. Long-term follow-up of neointimal coverage of sirolimus-eluting stents--evaluation with optical coherence tomography. Circ J.2009;73:2300-2307
47. Fuke S, Maekawa K, Kawamoto K, Saito H, Sato T, Hioka T, Ohe T. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J. 2007;71:220-225
48. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, Meier B, Hess OM. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol.2005;46:231-236
49. Li X, Han Y, Pang W, Li C, Xie X, Shyy JY, Zhu Y. Amp-activated protein kinase promotes the differentiation of endothelial progenitor cells. Arterioscler Thromb Vasc Biol.2008;28:1789-1795
50. Ii M, Losordo DW. Statins and the endothelium. Vascul Pharmacol.2007;46:1-9
51. Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T, Tanimoto T, Matsuo Y, Masho T, Kitabata H, Tsuda K, Tomobuchi Y, Akasaka T. Assessment of culprit lesion morphology in acute myocardial infarction:Ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol.2007;50:933-939
52. Grines CL, Bonow RO, Casey DE, Jr., Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents:A science advisory from the american heart association, american college of cardiology, society for cardiovascular angiography and interventions, american college of surgeons, and american dental association, with representation from the american college of physicians. J Am Dent Assoc.2007;138:652-655
53. Otake H, Shite J, Ako J, Shinke T, Tanino Y, Ogasawara D, Sawada T, Miyoshi N, Kato H, Koo BK, Honda Y, Fitzgerald PJ, Hirata K. Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography. JACC Cardiovasc Interv.2009;2:459-466
54. Nusca A, Melfi R, Di Sciascio G. Percutaneous coronary interventions and statins therapy. Ther Adv Cardiovasc Dis.2008;2:101-107
1. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans:Delayed healing and late thrombotic risk. JAm Coll Cardiol.2006;48:193-202
2. Trabattoni D, Fabbiocchi F, Montorsi P, Ravagnani P, Galli S, Teruzzi G, Calligaris G, De Martini S, Bartorelli AL. Stent thrombosis after sirolimus- and paclitaxel-eluting stent implantation in daily clinical practice:Analysis of a single center registry. Catheter Cardiovasc Interv.2007;70:415-421
3. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice.4-year results from a large 2-institutional cohort study. J Am Coll Cardiol.2008;52:1134-1140
4. Grines CL, Bonow RO, Casey DE, Jr., Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents:A science advisory from the american heart association, american college of cardiology, society for cardiovascular angiography and interventions, american college of surgeons, and american dental association, with representation from the american college of physicians. Circulation.2007; 115:813-818
5. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis:Strut coverage as a marker of endothelialization. Circulation.2007;115:2435-2441
6. Vita JA. Endothelial function. Circulation.2011;124:e906-912
7. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-st-elevation acute coronary syndrome:The clopidogrel in unstable angina to prevent recurrent ischemic events (cure) trial. Circulation. 2004;110:1202-1208
8. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:The pci-cure study. Lancet.2001;358:527-533
9. Jolly SS, Pogue J, Haladyn K, Peters RJ, Fox KA, Avezum A, Gersh BJ, Rupprecht HJ, Yusuf S, Mehta SR. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention:Insights from the pci-cure study. Eur Heart J.2009;30:900-907
10. Collaboration. AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ.2002;324:71-86
11. Cannon CP. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic athero thrombosis (caprie trial). Am J Cardiol.2002;90:760-762
12. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (classics). Circulation.2000; 102:624-629
13. Maier JA. Endothelial cells and magnesium:Implications in atherosclerosis. Clin Sci (Lond).2012; 122:397-407
14. Fuke S, Maekawa K, Kawamoto K, Saito H, Sato T, Hioka T, Ohe T. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J. 2007;71:220-225
15. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, Meier B, Hess OM. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol.2005;46:231-236
16. Fukuda D, Enomoto S, Shirakawa I, Nagai R, Sata M. Fluvastatin accelerates re-endothelialization impaired by local sirolimus treatment. Eur J Pharmacol. 2009;612:87-92
17. Bell DM, Johns TE, Lopez LM. Endothelial dysfunction:Implications for therapy of cardiovascular diseases. Ann Pharmacother.1998;32:459-470
18. von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Graf I, Schomig A. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J. 2007;28:1814-1819
19. Smith SC, Jr., Feldman TE, Hirshfeld JW, Jr., Jacobs AK, Kern MJ, King SB,3rd, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B. Acc/aha/scai 2005 guideline update for percutaneous coronary intervention:A report of the american college of cardiology/american heart association task force on practice guidelines (acc/aha/scai writing committee to update the 2001 guidelines for percutaneous coronary intervention). J Am Coll Cardiol.2006;47:el-121
20. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (current-oasis 7):A randomised factorial trial. Lancet.2010;376:1233-1243
21. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.N Engl J Med.2010;363:930-942
22. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA.2007;297:159-168
1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med.2002;346:1773-1780
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med.2003;349:1315-1323
3. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008;52:1134-1140
4. Trabattoni D, Fabbiocchi F, Montorsi P, Ravagnani P, Galli S, Teruzzi G, Calligaris G, De Martini S, Bartorelli AL. Stent thrombosis after sirolimus-and paclitaxel-eluting stent implantation in daily clinical practice:Analysis of a single center registry. Catheter Cardiovasc Interv.2007;70:415-421
5. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA.2005;293:2126-2130
6. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier B, Windecker S. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation.2007;115:2426-2434
7. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis:Strut coverage as a marker of endothelialization. Circulation.2007;115:2435-2441
8. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK, Burke AP, Kolodgie FD, Virmani R. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients:An autopsy study. Circulation.2008; 118:1138-1145
9. Bezerra HG, Costa MA, Guagliumi G, Rollins AM, Simon DI. Intracoronary optical coherence tomography:A comprehensive review clinical and research applications. JACC Cardiovasc Interv.2009;2:1035-1046
10. Prati F, Regar E, Mintz GS, Arbustini E, Di Mario C, Jang IK, Akasaka T, Costa M, Guagliumi G, Grube E, Ozaki Y, Pinto F, Serruys PW. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography:Physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J. 2010;31:401-415
11. Choi HH, Kim JS, Yoon DH, Hong KS, Kim TH, Kim BK, Ko YG, Choi D, Jang Y, Hong MK. Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation:Comparison with sirolimus-eluting stent using optical coherence tomography. Int J Cardiovasc Imaging.2011
12. Inoue T, Shite J, Yoon J, Shinke T, Otake H, Sawada T, Kawamori H, Katoh H, Miyoshi N, Yoshino N, Kozuki A, Hariki H, Hirata K. Optical coherence evaluation of everolimus-eluting stents 8 months after implantation. Heart.2011;97:1379-1384
13. Ishigami K, Uemura S, Morikawa Y, Soeda T, Okayama S, Nishida T, Takemoto Y, Onoue K, Somekawa S, Takeda Y, Kawata H, Horii M, Saito Y. Long-term follow-up of neointimal coverage of sirolimus-eluting stents--evaluation with optical coherence tomography. Circ J.2009;73:2300-2307
14. Katoh H, Shite J, Shinke T, Matsumoto D, Tanino Y, Ogasawara D, Sawada T, Miyoshi N, Kawamori H, Yoshino N, Hirata K. Delayed neointimalization on sirolimus-eluting stents:6-month and 12-month follow up by optical coherence tomography. Circ J.2009;73:1033-1037
15. Kim JS, Fan C, Choi D, Jang IK, Lee JM, Kim TH, Park SM, Paik SI, Ko YG, Hong MK, Jang Y, Chung N. Different patterns of neointimal coverage between acute coronary syndrome and stable angina after various types of drug-eluting stents implantation; 9-month follow-up optical coherence tomography study. Int J Cardiol. 2011;146:341-346
16. Kim JS, Jang IK, Fan C, Kim TH, Park SM, Choi EY, Lee SH, Ko YG, Choi D, Hong MK, Jang Y. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography:The endeavor oct trial. JACC Cardiovasc Interv.2009;2:1240-1247
17. Kim JS, Kim TH, Fan C, Lee JM, Kim W, Ko YG, Choi D, Hong MK, Jang Y. Comparison of neointimal coverage of sirolimus-eluting stents and paclitaxel-eluting stents using optical coherence tomography at 9 months after implantation. Circ J. 2009;74:320-326
18. Kim JS, Shin DH, Kim BK, Ko YG, Choi D, Jang Y, Hong MK. Optical coherence tomographic comparison of neointimal coverage between sirolimus-and resolute zotarolimus-eluting stents at 9 months after stent implantation. Int J Cardiovasc Imaging.2011
19. Kim TH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK. Long-term (>/=2 years) follow-up optical coherence tomographic study after sirolimus-and paclitaxel-eluting stent implantation:Comparison to 9-month follow-up results. Int J Cardiovasc Imaging.2011
20. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada T, Paredes OL, Hirata K, Yokoyama M. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up:Evaluated by optical coherence tomography. Eur Heart J. 2007;28:961-967
21. Takano M, Inami S, Jang IK, Yamamoto M, Murakami D, Seimiya K, Ohba T, Mizuno K. Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. Am J Cardiol. 2007;99:1033-1038
22. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333-342
23. Gonzalo N, Barlis P, Serruys PW, Garcia-Garcia HM, Onuma Y, Ligthart J, Regar E. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for st-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina:Insights from optical coherence tomography. JACC Cardiovasc Interv.2009;2:445-452
24. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus-or paclitaxel-eluting stents. Circulation.2005;112:270-278
25. Miyazaki S, Hiasa Y, Kishi K. Very late thrombosis after subintimal sirolimus-eluting stent implantation during percutaneous coronary intervention for chronic total occlusion. J Invasive Cardiol.2010;22:E162-165
26. Ozaki Y, Okumura M, Ismail TF, Naruse H, Hattori K, Kan S, Ishikawa M, Kawai T, Takagi Y, Ishii J, Prati F, Serruys PW. The fate of incomplete stent apposition with drug-eluting stents:An optical coherence tomography-based natural history study. Eur Heart J.2010;31:1470-1476
27. McDaniel MC, Eshtehardi P, Sawaya FJ, Douglas JS, Jr., Samady H. Contemporary clinical applications of coronary intravascular ultrasound. JACC Cardiovasc Interv. 2011;4:1155-1167
28. Suzuki Y, Ikeno F, Koizumi T, Tio F, Yeung AC, Yock PG, Fitzgerald PJ, Fearon WF. In vivo comparison between optical coherence tomography and intravascular ultrasound for detecting small degrees of in-stent neointima after stent implantation. JACC Cardiovasc Interv.2008;1:168-173
1. Mintz GS. What to do about late incomplete stent apposition? Circulation. 2007;115:2379-2381
2. Alfonso F, Suarez A, Angiolillo DJ, Sabate M, Escaned J, Moreno R, Hernandez R, Banuelos C, Macaya C. Findings of intravascular ultrasound during acute stent thrombosis. Heart.2004;90:1455-1459
3. Cheneau E, Leborgne L, Mintz GS, Kotani J, Pichard AD, Satler LF, Canos D, Castagna M, Weissman NJ, Waksman R. Predictors of subacute stent thrombosis: Results of a systematic intravascular ultrasound study. Circulation.2003; 108:43-47
4. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, Nishikawa H, Hiasa Y, Muramatsu T, Meguro T, Inoue N, Honda H, Hayashi Y, Miyazaki S, Oshima S, Honda T, Shiode N, Namura M, Sone T, Nobuyoshi M, Kita T, Mitsudo K. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation.2009; 119:987-995
5. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents:An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol.2006;48:2584-2591
6. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabate M, Escaned J, Banuelos C, Fernandez-Ortiz A, Macaya C. Drug-eluting stent thrombosis:Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954-959
7. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (last) events with drug-eluting stents. J Am Coll Cardiol.2005;45:2088-2092
8. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA.2005;293:2126-2130
9. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation.2003; 108:1701-1706
10. Heller LI, Shemwell KC, Hug K. Late stent thrombosis in the absence of prior intracoronary brachytherapy. Catheter Cardiovasc Interv.2001;53:23-28
11. Wang F, Stouffer GA, Waxman S, Uretsky BF. Late coronary stent thrombosis:Early vs Late stent thrombosis in the stent era. Catheter Cardiovasc Interv. 2002;55:142-147
12. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, van der Wieken LR, Tijssen JG, Rensing BJ, Patterson M. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355:1105-1113
13. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med.2006:355:1093-1104
14. Caixeta A, Leon MB, Lansky AJ, Nikolsky E, Aoki J, Moses JW, Schofer J, Morice MC, Schampaert E, Kirtane AJ, Popma JJ, Parise H, Fahy M, Mehran R.5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J Am Coll Cardiol.2009;54:894-902
15. Schampaert E, Moses JW, Schofer J, Schluter M, Gershlick AH, Cohen EA, Palisaitis DA, Breithardt G, Donohoe DJ, Wang H, Popma JJ, Kuntz RE, Leon MB. Sirolimus-eluting stents at two years:A pooled analysis of sirius, e-sirius, and c-sirius with emphasis on late revascularizations and stent thromboses. Am J Cardiol. 2006;98:36-41
16. Hoffmann R, Morice MC, Moses JW, Fitzgerald PJ, Mauri L, Breithardt G, Schofer J, Serruys PW, Stoll HP, Leon MB. Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events:Intravascular ultrasound analysis from the multicentre, randomised, ravel, e-sirius and sirius trials. Heart.2008;94:322-328
17. Daemen J, Tanimoto S, Garcia-Garcia HM, Kukreja N, van de Sande M, Sianos G, de Jaegere PP, van Domburg RT, Serruys PW. Comparison of three-year clinical outcome of sirolimus-and paclitaxel-eluting stents versus bare metal stents in patients with st-segment elevation myocardial infarction (from the research and t-search registries). Am J Cardiol.2007;99:1027-1032
18. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis:Strut coverage as a marker of endothelialization. Circulation.2007; 115:2435-2441
19. Ishigami K, Uemura S, Morikawa Y, Soeda T, Okayama S, Nishida T, Takemoto Y, Onoue K, Somekawa S, Takeda Y, Kawata H, Horii M, Saito Y. Long-term follow-up of neointimal coverage of sirolimus-eluting stents--evaluation with optical coherence tomography. Circ J.2009;73:2300-2307
20. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice:Data from a large two-institutional cohort study. Lancet.2007;369:667-678
21. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK, Burke AP, Kolodgie FD, Virmani R. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients:An autopsy study. Circulation.2008;118:1138-1145
22. Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW. Angiographic stent thrombosis after routine use of drug-eluting stents in st-segment elevation myocardial infarction:The importance of thrombus burden. J Am Coll Cardiol.2007;50:573-583
23. Sheu ML, Ho FM, Yang RS, Chao KF, Lin WW, Lin-Shiau SY, Liu SH. High glucose induces human endothelial cell apoptosis through a phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway. Arterioscler Thromb Vase Biol. 2005;25:539-545
24. Varma S, Lal BK, Zheng R, Breslin JW, Saito S, Pappas PJ, Hobson RW,2nd, Duran WN. Hyperglycemia alters pi3k and akt signaling and leads to endothelial cell proliferative dysfunction. Am J Physiol Heart Circ Physiol.2005;289:H 1744-1751
25. Colmenarez HJ, Escaned J, Fernandez C, Lobo L, Cano S, del Angel JG, Alfonso F, Jimenez P, Banuelos C, Gonzalo N, Garcia E, Hernandez R, Macaya C. Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization:A systematic review and meta-analysis. J Am Coll Cardiol.2010;55:1854-1866
26. Galassi AR, Tomasello SD, Costanzo L, Campisano MB, Barrano G, Tamburino C. Long-term clinical and angiographic results of sirolimus-eluting stent in complex coronary chronic total occlusion revascularization:The sector registry. J Interv Cardiol.2011;24:426-436
27. Van den Branden BJ, Rahel BM, Laarman GJ, Slagboom T, Kelder JC, Ten Berg JM, Suttorp MJ. Five-year clinical outcome after primary stenting of totally occluded native coronary arteries:A randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (prison ii study). EuroIntervention.2011;7:1189-1196
28. Park KW, Chae IH, Lim DS, Han KR, Yang HM, Lee HY, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Jo SH, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Gwon HC, Jang YS, Kim HS. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention:The excellent (efficacy of xience/promus versus cypher to reduce late loss after stenting) randomized trial. J Am Coll Cardiol. 2011;58:1844-1854
29. Planer D, Smits PC, Kereiakes DJ, Kedhi E, Fahy M, Xu K, Serruys PW, Stone GW. Comparison of everolimus-and paclitaxel-eluting stents in patients with acute and stable coronary syndromes:Pooled results from the spirit (a clinical evaluation of the xience v everolimus eluting coronary stent system) and compare (a trial of everolimus-eluting stents and paclitaxel-eluting stents for coronary revascularization in daily practice) trials. JACC Cardiovasc Interv.2011;4:1104-1115
30. Raber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Juni P, Serruys PW, Windecker S. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents:A prospective cohort study. Circulation. 2012;125:1110-1121
31. Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Juni P, Schomig A, Windecker S, Kastrati A. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention:A pooled analysis of individual patient data from the isar-test 3, isar-test 4, and leaders randomized trials. Eur Heart J.2012
32. Kim JS, Hong MK, Fan C, Kim TH, Shim JM, Park SM, Ko YG, Choi D, Jang Y. Intracoronary thrombus formation after drug-eluting stents implantation:Optical coherence tomographic study. Am Heart J.2010;159:278-283
33. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada T, Paredes OL, Hirata K, Yokoyama M. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up:Evaluated by optical coherence tomography. Eur Heart J. 2007;28:961-967
34. Otake H, Shite J, Ako J, Shinke T, Tanino Y, Ogasawara D, Sawada T, Miyoshi N, Kato H, Koo BK, Honda Y, Fitzgerald PJ, Hirata K. Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography. JACC Cardiovasc Interv.2009;2:459-466
35. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Muller KM. Acute and chronic tissue response to coronary stent implantation:Pathologic findings in human specimen. J Am Coll Cardiol.2000;35:157-163
36. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans:Delayed healing and late thrombotic risk. J Am Coll Cardiol.2006;48:193-202
37. Grines CL, Bonow RO, Casey DE, Jr., Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents:A science advisory from the american heart association, american college of cardiology, society for cardiovascular angiography and interventions, american college of surgeons, and american dental association, with representation from the american college of physicians. Circulation. 2007;115:813-818
38. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents:Importance of delayed healing. Arterioscler Thromb Vasc Biol.2007;27:1500-1510
39. Tsai TT, Nallamothu BK, Bates ER. Letter by tsai et al regarding article, "Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus-and paclitaxel-eluting stents". Circulation.2006;114:e362; author reply e363
40. Raber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, Cook S, Moschovitis A, Vogel R, Kalesan B, Seiler C, Eberli F, Luscher TF, Meier B, Juni P, Windecker S. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents:Results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization late trial. Circulation.2011; 123:2819-2828,2816 p following 2828
41. Degertekin M, Serruys PW, Tanabe K, Lee CH, Sousa JE, Colombo A, Morice MC, Ligthart JM, de Feyter PJ. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions:An intravascular ultrasound analysis. Circulation.2003;108:2747-2750
42. Mintz GS, Weissman NJ. Intravascular ultrasound in the drug-eluting stent era. J Am Coll Cardiol.2006;48:421-429
43. Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM, Han KH, Kang DH, Song JK, Kim JJ, Park SW, Park SJ. Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation. Circulation.2004; 109:881-886
44. Mintz GS, Shah VM, Weissman NJ. Regional remodeling as the cause of late stent malapposition. Circulation.2003; 107:2660-2663
45. Tanabe K, Serruys PW, Degertekin M, Grube E, Guagliumi G, Urbaszek W, Bonnier J, Lablanche JM, Siminiak T, Nordrehaug J, Figulla H, Drzewiecki J, Banning A, Hauptmann K, Dudek D, Bruining N, Hamers R, Hoye A, Ligthart JM, Disco C, Koglin J, Russell ME, Colombo A. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents:Insights from the randomized taxus ii trial. Circulation.2005; 111:900-905
46. Ako J, Morino Y, Honda Y, Hassan A, Sonoda S, Yock PG, Leon MB, Moses JW, Bonneau HN, Fitzgerald PJ. Late incomplete stent apposition after sirolimus-eluting stent implantation:A serial intravascular ultrasound analysis. J Am Coll Cardiol. 2005;46:1002-1005
47. Hong MK, Mintz GS, Lee CW, Park DW, Park KM, Lee BK, Kim YH, Song JM, Han KH, Kang DH, Cheong SS, Song JK, Kim JJ, Park SW, Park SJ. Late stent malapposition after drug-eluting stent implantation:An intravascular ultrasound analysis with long-term follow-up. Circulation.2006;113:414-419
48. Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A, Guagliumi G, Wijns W, Lindeboom WK, Ligthart J, de Feyter PJ, Morice MC. Intravascular ultrasound findings in the multicenter, randomized, double-blind ravel (randomized study with the sirolimus-eluting velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions) trial. Circulation. 2002;106:798-803
49. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier B, Windecker S. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation.2007;115:2426-2434
50. Hassan AK, Bergheanu SC, Stijnen T, van der Hoeven BL, Snoep JD, Plevier JW, Schalij MJ, Wouter Jukema J. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J.2009;31:1172-1180
51. Gonzalo N, Barlis P, Serruys PW, Garcia-Garcia HM, Onuma Y, Ligthart J, Regar E. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for st-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina:Insights from optical coherence tomography. JACC Cardiovasc Interv.2009;2:445-452
52. Kubo T, Imanishi T, Kitabata H, Kuroi A, Ueno S, Yamano T, Tanimoto T, Matsuo Y, Masho T, Takarada S, Tanaka A, Nakamura N, Mizukoshi M, Tomobuchi Y, Akasaka T. Comparison of vascular response after sirolimus-eluting stent implantation between patients with unstable and stable angina pectoris:A serial optical coherence tomography study. JACC Cardiovasc Imaging.2008; 1:475-484
53. Ozaki Y, Okumura M, Ismail TF, Naruse H, Hattori K, Kan S, Ishikawa M, Kawai T, Takagi Y, Ishii J, Prati F, Serruys PW. The fate of incomplete stent apposition with drug-eluting stents:An optical coherence tomography-based natural history study. Eur Heart J.2010;31:1470-1476
54. Lee CW, Kang SJ, Park DW, Lee SH, Kim YH, Kim JJ, Park SW, Mintz GS, Park SJ. Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation. J Am Coll Cardiol. 2010;55:1936-1942
55. Nakazawa G, Vorpahl M, Finn AV, Narula J, Virmani R. One step forward and two steps back with drug-eluting-stents:From preventing restenosis to causing late thrombosis and nouveau atherosclerosis. JACC Cardiovasc Imaging. 2009;2:625-628
56. Popma JJ, Tiroch K, Almonacid A, Cohen S, Kandzari DE, Leon MB. A qualitative and quantitative angiographic analysis of stent fracture late following sirolimus-eluting stent implantation. Am J Cardiol.2009; 103:923-929
57. Aoki J, Nakazawa G, Tanabe K, Hoye A, Yamamoto H, Nakayama T, Onuma Y, Higashikuni Y, Otsuki S, Yagishita A, Yachi S, Nakajima H, Hara K. Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv.2007;69:380-386
58. Lee SH, Park JS, Shin DG, Kim YJ, Hong GR, Kim W, Shim BS. Frequency of stent fracture as a cause of coronary restenosis after sirolimus-eluting stent implantation. Am J Cardiol.2007; 100:627-630
59. Ito T, Terashima M, Kaneda H, Nasu K, Kinoshita Y, Habara M, Tsuchikane E, Suzuki T. Very late sirolimus-eluting stent thrombosis due to stent fracture and late-acquired incomplete stent apposition detected on multislice computed tomography. Circ J.2011;75:2716-2717
60. Nakazawa G, Finn AV, Vorpahl M, Ladich E, Kutys R, Balazs I, Kolodgie FD, Virmani R. Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. J Am Coll Cardiol.2009;54:1924-1931
61. Doi H, Maehara A, Mintz GS, Tsujita K, Kubo T, Castellanos C, Liu J, Yang J, Oviedo C, Aoki J, Franklin-Bond T, Dasgupta N, Lansky AJ, Dangas GD, Stone GW, Moses JW, Mehran R, Leon MB. Classification and potential mechanisms of intravascular ultrasound patterns of stent fracture. Am J Cardiol.2009; 103:818-823
62. Hanna NN, Gaglia MA, Jr., Torguson R, Ben-Dor I, Gonzalez MA, Collins SD, Syed AI, Maluenda G, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R. Three-year outcomes following sirolimus-versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the rewards registry). Am J Cardiol.2010; 106:504-510
63. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333-342
64. Kim TH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK. Long-term (>/=2 years) follow-up optical coherence tomographic study after sirolimus-and paclitaxel-eluting stent implantation:Comparison to 9-month follow-up results. Int J Cardiovasc Imaging.2010;27:875-881
65. Murakami D, Takano M, Yamamoto M, Inami S, Ohba T, Seino Y, Mizuno K. Advanced neointimal growth is not associated with a low risk of in-stent thrombus. Optical coherence tomographic findings after first-generation drug-eluting stent implantation. Circ J.2009;73:1627-1634
66. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation.2002; 105:2974-2980
67. Ge L, Airoldi F, Iakovou I, Cosgrave J, Michev I, Sangiorgi GM, Montorfano M, Chieffo A, Carlino M, Corvaja N, Colombo A. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique:Importance of final kissing balloon post-dilation. J Am Coll Cardiol. 2005;46:613-620
68. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent:Should we be cautious? Circulation.2004; 109:701-705
69. Afergan E, Ben David M, Epstein H, Koroukhov N, Gilhar D, Rohekar K, Danenberg HD, Golomb G. Liposomal simvastatin attenuates neointimal hyperplasia in rats. AAPS J.2010;12:181-187
70. Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T, Onishi T, Iida O, Sera F, Nanto S, Hori M, Nagata S. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation:Comparison with bare-metal stents. Circulation.2007; 116:910-916
71. Takano M, Yamamoto M, Xie Y, Murakami D, Inami S, Okamatsu K, Seimiya K, Ohba T, Seino Y, Mizuno K. Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angioscopy. Heart.2007;93:1533-1536
72. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus-or paclitaxel-eluting stents. Circulation.2005; 112:270-278
73. Rogers C, Parikh S, Seifert P, Edelman ER. Endogenous cell seeding. Remnant endothelium after stenting enhances vascular repair. Circulation.1996;94:2909-2914
74. Drachman DE, Edelman ER, Seifert P, Groothuis AR, Bornstein DA, Kamath KR, Palasis M, Yang D, Nott SH, Rogers C. Neointimal thickening after stent delivery of paclitaxel:Change in composition and arrest of growth over six months. J Am Coll Cardiol.2000;36:2325-2332
75. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation.2001; 104:1188-1193
76. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents:Are human and animal studies comparable? Heart.2003;89:133-138
77. Parry TJ, Brosius R, Thyagarajan R, Carter D, Argentieri D, Falotico R, Siekierka J. Drug-eluting stents:Sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol.2005;524:19-29
78. Marks AR. Rapamycin:Signaling in vascular smooth muscle. Transplant Proc. 2003;35:231S-233S
79. Fukuda D, Sata M, Tanaka K, Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation.2005; 111:926-931
80. Jaschke B, Michaelis C, Milz S, Vogeser M, Mund T, Hengst L, Kastrati A, Schomig A, Wessely R. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res.2005;68:483-492
81. Tanner FC, Boehm M, Akyurek LM, San H, Yang ZY, Tashiro J, Nabel GJ, Nabel EG. Differential effects of the cyclin-dependent kinase inhibitors p27(kipl), p21(cip1), and pl6(ink4) on vascular smooth muscle cell proliferation. Circulation. 2000; 101:2022-2025
82. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabbani LE. Role for p27(kipl) in vascular smooth muscle cell migration. Circulation.2001; 103:2967-2972
83. Vinals F, Chambard JC, Pouyssegur J. P70 s6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. J Biol Chem. 1999;274:26776-26782
84. Hwang CW, Levin AD, Jonas M, Li PH, Edelman ER. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation.2005; 111:1619-1626
85. Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H, Neumann FJ. Inflammation and long-term mortality after non-st elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation.2002;105:1412-1415
86. Kim BK, Kim JS, Oh C, Ko YG, Choi D, Jang Y, Hong MK. Impact of preprocedural high-sensitivity c-reactive protein levels on uncovered stent struts:An optical coherence tomography study after drug-eluting stent implantation. Clin Cardiol. 2011;34:97-101
87. Park DW, Lee CW, Yun SC, Kim YH, Hong MK, Kim JJ, Park SW, Park SJ. Prognostic impact of preprocedural c reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. Heart.2007;93:1087-1092
2. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice.4-year results from a large 2-institutional cohort study. J Am Coll Cardiol.2008;52:1134-1140
3. Trabattoni D, Fabbiocchi F, Montorsi P, Ravagnani P, Galli S, Teruzzi G, Calligaris G, De Martini S, Bartorelli AL. Stent thrombosis after sirolimus- and paclitaxel-eluting stent implantation in daily clinical practice:Analysis of a single center registry. Catheter Cardiovasc Interv.2007;70:415-421
4. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents:A cause for concern. Circulation. 2007;115:1440-1455; discussion 1455
5. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis:Strut coverage as a marker of endothelialization. Circulation.2007; 115:2435-2441
6. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents:An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584-2591
7. Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, Feres F, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation.2003;107:381-383
8. Prati F, Zimarino M, Stabile E, Pizzicannella G, Fouad T, Rabozzi R, Filippini A, Pizzicannella J, Cera M, De Caterina R. Does optical coherence tomography identify arterial healing after stenting? An in vivo comparison with histology, in a rabbit carotid model. Heart.2008;94:217-221
9. Suzuki Y, Ikeno F, Koizumi T, Tio F, Yeung AC, Yock PG, Fitzgerald PJ, Fearon WF. In vivo comparison between optical coherence tomography and intravascular ultrasound for detecting small degrees of in-stent neointima after stent implantation. JACC Cardiovasc Interv.2008;1:168-173
10. Ong AT, Aoki J, Kutryk MJ, Serruys PW. How to accelerate the endothelialization of stents. Arch Mal Coeur Vaiss.2005;98:123-126
11. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science.1997;275:964-967
12. Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, Oh BH, Lee MM, Park YB. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol. 2004;24:288-293
13. Banerjee S, Brilakis E, Zhang S, Roesle M, Lindsey J, Philips B, Blewett CG, Terada LS. Endothelial progenitor cell mobilization after percutaneous coronary intervention. Atherosclerosis.2006; 189:70-75
14. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:E1-7
15. Matsuo Y, Imanishi T, Hayashi Y, Tomobuchi Y, Kubo T, Hano T, Akasaka T. The effect of senescence of endothelial progenitor cells on in-stent restenosis in patients undergoing coronary stenting. Intern Med.2006;45:581-587
16. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, Grunwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (topcare-ami). Circulation.2002;106:3009-3017
17. Schachinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, Abolmaali ND, Vogl TJ, Hofmann WK, Martin H, Dimmeler S, Zeiher AM. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction:Final one-year results of the topcare-ami trial. J Am Coll Cardiol.2004;44:1690-1699
18. Kawamoto A, Asahara T, Losordo DW. Transplantation of endothelial progenitor cells for therapeutic neovascularization. Cardiovasc Radiat Med.2002;3:221-225
19. Spadaccio C, Pollari F, Casacalenda A, Alfano G, Genovese J, Covino E, Chello M. Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery:A randomized control study. J Cardiovasc Pharmacol.2010;55:30-38
20. Xu J, Liu X, Chen J, Zacharek A, Cui X, Savant-Bhonsale S, Liu Z, Chopp M. Simvastatin enhances bone marrow stromal cell differentiation into endothelial cells via notch signaling pathway. Am J Physiol Cell Physiol.2009;296:C535-543
21. Suzuki G, Iyer V, Cimato T, Canty JM, Jr. Pravastatin improves function in hibernating myocardium by mobilizing cd133+ and ckit+ bone marrow progenitor cells and promoting myocytes to reenter the growth phase of the cardiac cell cycle. Circ Res.2009; 104:255-264,210p following 264
22. Hristov M, Fach C, Becker C, Heussen N, Liehn EA, Blindt R, Hanrath P, Weber C. Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. Atherosclerosis.2007;192:413-420
23. Kuwana M, Okazaki Y, Kaburaki J. Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod Rheumatol. 2009;19:530-535
24. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med.2002;346:1773-1780
25. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med.2003;349:1315-1323
26. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA.2005;293:2126-2130
27. Fukuda D, Enomoto S, Shirakawa I, Nagai R, Sata M. Fluvastatin accelerates re-endothelialization impaired by local sirolimus treatment. Eur J Pharmacol. 2009;612:87-92
28. Hibbert B, Ma X, Pourdjabbar A, Simard T, Rayner K, Sun J, Chen YX, Filion L, O'Brien ER. Pre-procedural atorvastatin mobilizes endothelial progenitor cells: Clues to the salutary effects of statins on healing of stented human arteries. PLoS One.2011;6:e16413
29. Hong SJ, Choi SC, Kim JS, Shim WJ, Park SM, Ahn CM, Park JH, Kim YH, Lim DS. Low-dose versus moderate-dose atorvastatin after acute myocardial infarction:8-month effects on coronary flow reserve and angiogenic cell mobilisation. Heart.2010;96:756-764
30. Cho JS, Jeong MH, Sim DS, Hong YJ, Lim KS, Kim JH, Kim HD, Baek JY, Yoon HJ, Her SH, Jin SW, Ahn Y, Cho JG, Park JC, Kang JC. Effects of combined therapy with ezetimibe plus simvastatin after drug-eluting stent implantation in a porcine coronary restenosis model. J Korean Med Sci. 2009;25:716-722
31. Bezerra HG, Costa MA, Guagliumi G, Rollins AM, Simon DI. Intracoronary optical coherence tomography:A comprehensive review clinical and research applications. JACC Cardiovasc Interv.2009;2:1035-1046
32. Prati F, Regar E, Mintz GS, Arbustini E, Di Mario C, Jang IK, Akasaka T, Costa M, Guagliumi G, Grube E, Ozaki Y, Pinto F, Serruys PW. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography:Physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J.2010;31:401-415
33. Kim JS, Fan C, Choi D, Jang IK, Lee JM, Kim TH, Park SM, Paik SI, Ko YG, Hong MK, Jang Y, Chung N. Different patterns of neointimal coverage between acute coronary syndrome and stable angina after various types of drug-eluting stents implantation; 9-month follow-up optical coherence tomography study. Int J Cardiol.2009
34. Katoh H, Shite J, Shinke T, Matsumoto D, Tanino Y, Ogasawara D, Sawada T, Miyoshi N, Kawamori H, Yoshino N, Hirata K. Delayed neointimalization on sirolimus-eluting stents:6-month and 12-month follow up by optical coherence tomography. Circ J.2009;73:1033-1037
35. Kim TH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK. Long-term (>/=2 years) follow-up optical coherence tomographic study after sirolimus-and paclitaxel-eluting stent implantation:Comparison to 9-month follow-up results. Int J Cardiovasc Imaging.2010;27:875-881
36. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada T, Paredes OL, Hirata K, Yokoyama M. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up:Evaluated by optical coherence tomography. Eur Heart J.2007;28:961-967
37. Kim JS, Kim TH, Fan C, Lee JM, Kim W, Ko YG, Choi D, Hong MK, Jang Y. Comparison of neointimal coverage of sirolimus-eluting stents and paclitaxel-eluting stents using optical coherence tomography at 9 months after implantation. Circ J.2009;74:320-326
38. Hanna NN, Gaglia MA, Jr., Torguson R, Ben-Dor I, Gonzalez MA, Collins SD, Syed AI, Maluenda G, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R. Three-year outcomes following sirolimus-versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the rewards registry). Am J Cardiol.2010; 106:504-510
39. Choi HH, Kim JS, Yoon DH, Hong KS, Kim TH, Kim BK, Ko YG, Choi D, Jang Y, Hong MK. Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation:Comparison with sirolimus-eluting stent using optical coherence tomography. Int J Cardiovasc Imaging.2011
40. Smith SC, Jr., Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. Aha/acc guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease:2006 update: Endorsed by the national heart, lung, and blood institute. Circulation. 2006;113:2363-2372
41. Jaschke B, Michaelis C, Milz S, Vogeser M, Mund T, Hengst L, Kastrati A, Schomig A, Wessely R. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res.2005;68:483-492
42. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents:Are human and animal studies comparable? Heart.2003;89:133-138
43. Kong D, Melo LG, Mangi AA, Zhang L, Lopez-Ilasaca M, Perrella MA, Liew CC, Pratt RE, Dzau VJ. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation.2004; 109:1769-1775
44. Moreno PR, Sanz J, Fuster V. Promoting mechanisms of vascular health: Circulating progenitor cells, angiogenesis, and reverse cholesterol transport. J Am Coll Cardiol.2009;53:2315-2323
45. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, Dimmeler S. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation.2001;103:2885-2890
46. Ishigami K, Uemura S, Morikawa Y, Soeda T, Okayama S, Nishida T, Takemoto Y, Onoue K, Somekawa S, Takeda Y, Kawata H, Horii M, Saito Y. Long-term follow-up of neointimal coverage of sirolimus-eluting stents--evaluation with optical coherence tomography. Circ J.2009;73:2300-2307
47. Fuke S, Maekawa K, Kawamoto K, Saito H, Sato T, Hioka T, Ohe T. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J. 2007;71:220-225
48. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, Meier B, Hess OM. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol.2005;46:231-236
49. Li X, Han Y, Pang W, Li C, Xie X, Shyy JY, Zhu Y. Amp-activated protein kinase promotes the differentiation of endothelial progenitor cells. Arterioscler Thromb Vasc Biol.2008;28:1789-1795
50. Ii M, Losordo DW. Statins and the endothelium. Vascul Pharmacol.2007;46:1-9
51. Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T, Tanimoto T, Matsuo Y, Masho T, Kitabata H, Tsuda K, Tomobuchi Y, Akasaka T. Assessment of culprit lesion morphology in acute myocardial infarction:Ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol.2007;50:933-939
52. Grines CL, Bonow RO, Casey DE, Jr., Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents:A science advisory from the american heart association, american college of cardiology, society for cardiovascular angiography and interventions, american college of surgeons, and american dental association, with representation from the american college of physicians. J Am Dent Assoc.2007;138:652-655
53. Otake H, Shite J, Ako J, Shinke T, Tanino Y, Ogasawara D, Sawada T, Miyoshi N, Kato H, Koo BK, Honda Y, Fitzgerald PJ, Hirata K. Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography. JACC Cardiovasc Interv.2009;2:459-466
54. Nusca A, Melfi R, Di Sciascio G. Percutaneous coronary interventions and statins therapy. Ther Adv Cardiovasc Dis.2008;2:101-107
1. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans:Delayed healing and late thrombotic risk. JAm Coll Cardiol.2006;48:193-202
2. Trabattoni D, Fabbiocchi F, Montorsi P, Ravagnani P, Galli S, Teruzzi G, Calligaris G, De Martini S, Bartorelli AL. Stent thrombosis after sirolimus- and paclitaxel-eluting stent implantation in daily clinical practice:Analysis of a single center registry. Catheter Cardiovasc Interv.2007;70:415-421
3. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice.4-year results from a large 2-institutional cohort study. J Am Coll Cardiol.2008;52:1134-1140
4. Grines CL, Bonow RO, Casey DE, Jr., Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents:A science advisory from the american heart association, american college of cardiology, society for cardiovascular angiography and interventions, american college of surgeons, and american dental association, with representation from the american college of physicians. Circulation.2007; 115:813-818
5. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis:Strut coverage as a marker of endothelialization. Circulation.2007;115:2435-2441
6. Vita JA. Endothelial function. Circulation.2011;124:e906-912
7. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-st-elevation acute coronary syndrome:The clopidogrel in unstable angina to prevent recurrent ischemic events (cure) trial. Circulation. 2004;110:1202-1208
8. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:The pci-cure study. Lancet.2001;358:527-533
9. Jolly SS, Pogue J, Haladyn K, Peters RJ, Fox KA, Avezum A, Gersh BJ, Rupprecht HJ, Yusuf S, Mehta SR. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention:Insights from the pci-cure study. Eur Heart J.2009;30:900-907
10. Collaboration. AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ.2002;324:71-86
11. Cannon CP. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic athero thrombosis (caprie trial). Am J Cardiol.2002;90:760-762
12. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (classics). Circulation.2000; 102:624-629
13. Maier JA. Endothelial cells and magnesium:Implications in atherosclerosis. Clin Sci (Lond).2012; 122:397-407
14. Fuke S, Maekawa K, Kawamoto K, Saito H, Sato T, Hioka T, Ohe T. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J. 2007;71:220-225
15. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, Meier B, Hess OM. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol.2005;46:231-236
16. Fukuda D, Enomoto S, Shirakawa I, Nagai R, Sata M. Fluvastatin accelerates re-endothelialization impaired by local sirolimus treatment. Eur J Pharmacol. 2009;612:87-92
17. Bell DM, Johns TE, Lopez LM. Endothelial dysfunction:Implications for therapy of cardiovascular diseases. Ann Pharmacother.1998;32:459-470
18. von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Graf I, Schomig A. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J. 2007;28:1814-1819
19. Smith SC, Jr., Feldman TE, Hirshfeld JW, Jr., Jacobs AK, Kern MJ, King SB,3rd, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B. Acc/aha/scai 2005 guideline update for percutaneous coronary intervention:A report of the american college of cardiology/american heart association task force on practice guidelines (acc/aha/scai writing committee to update the 2001 guidelines for percutaneous coronary intervention). J Am Coll Cardiol.2006;47:el-121
20. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (current-oasis 7):A randomised factorial trial. Lancet.2010;376:1233-1243
21. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.N Engl J Med.2010;363:930-942
22. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA.2007;297:159-168
1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med.2002;346:1773-1780
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med.2003;349:1315-1323
3. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008;52:1134-1140
4. Trabattoni D, Fabbiocchi F, Montorsi P, Ravagnani P, Galli S, Teruzzi G, Calligaris G, De Martini S, Bartorelli AL. Stent thrombosis after sirolimus-and paclitaxel-eluting stent implantation in daily clinical practice:Analysis of a single center registry. Catheter Cardiovasc Interv.2007;70:415-421
5. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA.2005;293:2126-2130
6. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier B, Windecker S. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation.2007;115:2426-2434
7. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis:Strut coverage as a marker of endothelialization. Circulation.2007;115:2435-2441
8. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK, Burke AP, Kolodgie FD, Virmani R. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients:An autopsy study. Circulation.2008; 118:1138-1145
9. Bezerra HG, Costa MA, Guagliumi G, Rollins AM, Simon DI. Intracoronary optical coherence tomography:A comprehensive review clinical and research applications. JACC Cardiovasc Interv.2009;2:1035-1046
10. Prati F, Regar E, Mintz GS, Arbustini E, Di Mario C, Jang IK, Akasaka T, Costa M, Guagliumi G, Grube E, Ozaki Y, Pinto F, Serruys PW. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography:Physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J. 2010;31:401-415
11. Choi HH, Kim JS, Yoon DH, Hong KS, Kim TH, Kim BK, Ko YG, Choi D, Jang Y, Hong MK. Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation:Comparison with sirolimus-eluting stent using optical coherence tomography. Int J Cardiovasc Imaging.2011
12. Inoue T, Shite J, Yoon J, Shinke T, Otake H, Sawada T, Kawamori H, Katoh H, Miyoshi N, Yoshino N, Kozuki A, Hariki H, Hirata K. Optical coherence evaluation of everolimus-eluting stents 8 months after implantation. Heart.2011;97:1379-1384
13. Ishigami K, Uemura S, Morikawa Y, Soeda T, Okayama S, Nishida T, Takemoto Y, Onoue K, Somekawa S, Takeda Y, Kawata H, Horii M, Saito Y. Long-term follow-up of neointimal coverage of sirolimus-eluting stents--evaluation with optical coherence tomography. Circ J.2009;73:2300-2307
14. Katoh H, Shite J, Shinke T, Matsumoto D, Tanino Y, Ogasawara D, Sawada T, Miyoshi N, Kawamori H, Yoshino N, Hirata K. Delayed neointimalization on sirolimus-eluting stents:6-month and 12-month follow up by optical coherence tomography. Circ J.2009;73:1033-1037
15. Kim JS, Fan C, Choi D, Jang IK, Lee JM, Kim TH, Park SM, Paik SI, Ko YG, Hong MK, Jang Y, Chung N. Different patterns of neointimal coverage between acute coronary syndrome and stable angina after various types of drug-eluting stents implantation; 9-month follow-up optical coherence tomography study. Int J Cardiol. 2011;146:341-346
16. Kim JS, Jang IK, Fan C, Kim TH, Park SM, Choi EY, Lee SH, Ko YG, Choi D, Hong MK, Jang Y. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography:The endeavor oct trial. JACC Cardiovasc Interv.2009;2:1240-1247
17. Kim JS, Kim TH, Fan C, Lee JM, Kim W, Ko YG, Choi D, Hong MK, Jang Y. Comparison of neointimal coverage of sirolimus-eluting stents and paclitaxel-eluting stents using optical coherence tomography at 9 months after implantation. Circ J. 2009;74:320-326
18. Kim JS, Shin DH, Kim BK, Ko YG, Choi D, Jang Y, Hong MK. Optical coherence tomographic comparison of neointimal coverage between sirolimus-and resolute zotarolimus-eluting stents at 9 months after stent implantation. Int J Cardiovasc Imaging.2011
19. Kim TH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK. Long-term (>/=2 years) follow-up optical coherence tomographic study after sirolimus-and paclitaxel-eluting stent implantation:Comparison to 9-month follow-up results. Int J Cardiovasc Imaging.2011
20. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada T, Paredes OL, Hirata K, Yokoyama M. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up:Evaluated by optical coherence tomography. Eur Heart J. 2007;28:961-967
21. Takano M, Inami S, Jang IK, Yamamoto M, Murakami D, Seimiya K, Ohba T, Mizuno K. Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. Am J Cardiol. 2007;99:1033-1038
22. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333-342
23. Gonzalo N, Barlis P, Serruys PW, Garcia-Garcia HM, Onuma Y, Ligthart J, Regar E. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for st-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina:Insights from optical coherence tomography. JACC Cardiovasc Interv.2009;2:445-452
24. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus-or paclitaxel-eluting stents. Circulation.2005;112:270-278
25. Miyazaki S, Hiasa Y, Kishi K. Very late thrombosis after subintimal sirolimus-eluting stent implantation during percutaneous coronary intervention for chronic total occlusion. J Invasive Cardiol.2010;22:E162-165
26. Ozaki Y, Okumura M, Ismail TF, Naruse H, Hattori K, Kan S, Ishikawa M, Kawai T, Takagi Y, Ishii J, Prati F, Serruys PW. The fate of incomplete stent apposition with drug-eluting stents:An optical coherence tomography-based natural history study. Eur Heart J.2010;31:1470-1476
27. McDaniel MC, Eshtehardi P, Sawaya FJ, Douglas JS, Jr., Samady H. Contemporary clinical applications of coronary intravascular ultrasound. JACC Cardiovasc Interv. 2011;4:1155-1167
28. Suzuki Y, Ikeno F, Koizumi T, Tio F, Yeung AC, Yock PG, Fitzgerald PJ, Fearon WF. In vivo comparison between optical coherence tomography and intravascular ultrasound for detecting small degrees of in-stent neointima after stent implantation. JACC Cardiovasc Interv.2008;1:168-173
1. Mintz GS. What to do about late incomplete stent apposition? Circulation. 2007;115:2379-2381
2. Alfonso F, Suarez A, Angiolillo DJ, Sabate M, Escaned J, Moreno R, Hernandez R, Banuelos C, Macaya C. Findings of intravascular ultrasound during acute stent thrombosis. Heart.2004;90:1455-1459
3. Cheneau E, Leborgne L, Mintz GS, Kotani J, Pichard AD, Satler LF, Canos D, Castagna M, Weissman NJ, Waksman R. Predictors of subacute stent thrombosis: Results of a systematic intravascular ultrasound study. Circulation.2003; 108:43-47
4. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, Nishikawa H, Hiasa Y, Muramatsu T, Meguro T, Inoue N, Honda H, Hayashi Y, Miyazaki S, Oshima S, Honda T, Shiode N, Namura M, Sone T, Nobuyoshi M, Kita T, Mitsudo K. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation.2009; 119:987-995
5. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents:An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol.2006;48:2584-2591
6. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabate M, Escaned J, Banuelos C, Fernandez-Ortiz A, Macaya C. Drug-eluting stent thrombosis:Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954-959
7. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (last) events with drug-eluting stents. J Am Coll Cardiol.2005;45:2088-2092
8. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA.2005;293:2126-2130
9. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation.2003; 108:1701-1706
10. Heller LI, Shemwell KC, Hug K. Late stent thrombosis in the absence of prior intracoronary brachytherapy. Catheter Cardiovasc Interv.2001;53:23-28
11. Wang F, Stouffer GA, Waxman S, Uretsky BF. Late coronary stent thrombosis:Early vs Late stent thrombosis in the stent era. Catheter Cardiovasc Interv. 2002;55:142-147
12. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, van der Wieken LR, Tijssen JG, Rensing BJ, Patterson M. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355:1105-1113
13. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med.2006:355:1093-1104
14. Caixeta A, Leon MB, Lansky AJ, Nikolsky E, Aoki J, Moses JW, Schofer J, Morice MC, Schampaert E, Kirtane AJ, Popma JJ, Parise H, Fahy M, Mehran R.5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J Am Coll Cardiol.2009;54:894-902
15. Schampaert E, Moses JW, Schofer J, Schluter M, Gershlick AH, Cohen EA, Palisaitis DA, Breithardt G, Donohoe DJ, Wang H, Popma JJ, Kuntz RE, Leon MB. Sirolimus-eluting stents at two years:A pooled analysis of sirius, e-sirius, and c-sirius with emphasis on late revascularizations and stent thromboses. Am J Cardiol. 2006;98:36-41
16. Hoffmann R, Morice MC, Moses JW, Fitzgerald PJ, Mauri L, Breithardt G, Schofer J, Serruys PW, Stoll HP, Leon MB. Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events:Intravascular ultrasound analysis from the multicentre, randomised, ravel, e-sirius and sirius trials. Heart.2008;94:322-328
17. Daemen J, Tanimoto S, Garcia-Garcia HM, Kukreja N, van de Sande M, Sianos G, de Jaegere PP, van Domburg RT, Serruys PW. Comparison of three-year clinical outcome of sirolimus-and paclitaxel-eluting stents versus bare metal stents in patients with st-segment elevation myocardial infarction (from the research and t-search registries). Am J Cardiol.2007;99:1027-1032
18. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis:Strut coverage as a marker of endothelialization. Circulation.2007; 115:2435-2441
19. Ishigami K, Uemura S, Morikawa Y, Soeda T, Okayama S, Nishida T, Takemoto Y, Onoue K, Somekawa S, Takeda Y, Kawata H, Horii M, Saito Y. Long-term follow-up of neointimal coverage of sirolimus-eluting stents--evaluation with optical coherence tomography. Circ J.2009;73:2300-2307
20. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice:Data from a large two-institutional cohort study. Lancet.2007;369:667-678
21. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK, Burke AP, Kolodgie FD, Virmani R. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients:An autopsy study. Circulation.2008;118:1138-1145
22. Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW. Angiographic stent thrombosis after routine use of drug-eluting stents in st-segment elevation myocardial infarction:The importance of thrombus burden. J Am Coll Cardiol.2007;50:573-583
23. Sheu ML, Ho FM, Yang RS, Chao KF, Lin WW, Lin-Shiau SY, Liu SH. High glucose induces human endothelial cell apoptosis through a phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway. Arterioscler Thromb Vase Biol. 2005;25:539-545
24. Varma S, Lal BK, Zheng R, Breslin JW, Saito S, Pappas PJ, Hobson RW,2nd, Duran WN. Hyperglycemia alters pi3k and akt signaling and leads to endothelial cell proliferative dysfunction. Am J Physiol Heart Circ Physiol.2005;289:H 1744-1751
25. Colmenarez HJ, Escaned J, Fernandez C, Lobo L, Cano S, del Angel JG, Alfonso F, Jimenez P, Banuelos C, Gonzalo N, Garcia E, Hernandez R, Macaya C. Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization:A systematic review and meta-analysis. J Am Coll Cardiol.2010;55:1854-1866
26. Galassi AR, Tomasello SD, Costanzo L, Campisano MB, Barrano G, Tamburino C. Long-term clinical and angiographic results of sirolimus-eluting stent in complex coronary chronic total occlusion revascularization:The sector registry. J Interv Cardiol.2011;24:426-436
27. Van den Branden BJ, Rahel BM, Laarman GJ, Slagboom T, Kelder JC, Ten Berg JM, Suttorp MJ. Five-year clinical outcome after primary stenting of totally occluded native coronary arteries:A randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (prison ii study). EuroIntervention.2011;7:1189-1196
28. Park KW, Chae IH, Lim DS, Han KR, Yang HM, Lee HY, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Jo SH, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Gwon HC, Jang YS, Kim HS. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention:The excellent (efficacy of xience/promus versus cypher to reduce late loss after stenting) randomized trial. J Am Coll Cardiol. 2011;58:1844-1854
29. Planer D, Smits PC, Kereiakes DJ, Kedhi E, Fahy M, Xu K, Serruys PW, Stone GW. Comparison of everolimus-and paclitaxel-eluting stents in patients with acute and stable coronary syndromes:Pooled results from the spirit (a clinical evaluation of the xience v everolimus eluting coronary stent system) and compare (a trial of everolimus-eluting stents and paclitaxel-eluting stents for coronary revascularization in daily practice) trials. JACC Cardiovasc Interv.2011;4:1104-1115
30. Raber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Juni P, Serruys PW, Windecker S. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents:A prospective cohort study. Circulation. 2012;125:1110-1121
31. Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Juni P, Schomig A, Windecker S, Kastrati A. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention:A pooled analysis of individual patient data from the isar-test 3, isar-test 4, and leaders randomized trials. Eur Heart J.2012
32. Kim JS, Hong MK, Fan C, Kim TH, Shim JM, Park SM, Ko YG, Choi D, Jang Y. Intracoronary thrombus formation after drug-eluting stents implantation:Optical coherence tomographic study. Am Heart J.2010;159:278-283
33. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada T, Paredes OL, Hirata K, Yokoyama M. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up:Evaluated by optical coherence tomography. Eur Heart J. 2007;28:961-967
34. Otake H, Shite J, Ako J, Shinke T, Tanino Y, Ogasawara D, Sawada T, Miyoshi N, Kato H, Koo BK, Honda Y, Fitzgerald PJ, Hirata K. Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography. JACC Cardiovasc Interv.2009;2:459-466
35. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Muller KM. Acute and chronic tissue response to coronary stent implantation:Pathologic findings in human specimen. J Am Coll Cardiol.2000;35:157-163
36. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans:Delayed healing and late thrombotic risk. J Am Coll Cardiol.2006;48:193-202
37. Grines CL, Bonow RO, Casey DE, Jr., Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents:A science advisory from the american heart association, american college of cardiology, society for cardiovascular angiography and interventions, american college of surgeons, and american dental association, with representation from the american college of physicians. Circulation. 2007;115:813-818
38. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents:Importance of delayed healing. Arterioscler Thromb Vasc Biol.2007;27:1500-1510
39. Tsai TT, Nallamothu BK, Bates ER. Letter by tsai et al regarding article, "Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus-and paclitaxel-eluting stents". Circulation.2006;114:e362; author reply e363
40. Raber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, Cook S, Moschovitis A, Vogel R, Kalesan B, Seiler C, Eberli F, Luscher TF, Meier B, Juni P, Windecker S. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents:Results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization late trial. Circulation.2011; 123:2819-2828,2816 p following 2828
41. Degertekin M, Serruys PW, Tanabe K, Lee CH, Sousa JE, Colombo A, Morice MC, Ligthart JM, de Feyter PJ. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions:An intravascular ultrasound analysis. Circulation.2003;108:2747-2750
42. Mintz GS, Weissman NJ. Intravascular ultrasound in the drug-eluting stent era. J Am Coll Cardiol.2006;48:421-429
43. Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM, Han KH, Kang DH, Song JK, Kim JJ, Park SW, Park SJ. Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation. Circulation.2004; 109:881-886
44. Mintz GS, Shah VM, Weissman NJ. Regional remodeling as the cause of late stent malapposition. Circulation.2003; 107:2660-2663
45. Tanabe K, Serruys PW, Degertekin M, Grube E, Guagliumi G, Urbaszek W, Bonnier J, Lablanche JM, Siminiak T, Nordrehaug J, Figulla H, Drzewiecki J, Banning A, Hauptmann K, Dudek D, Bruining N, Hamers R, Hoye A, Ligthart JM, Disco C, Koglin J, Russell ME, Colombo A. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents:Insights from the randomized taxus ii trial. Circulation.2005; 111:900-905
46. Ako J, Morino Y, Honda Y, Hassan A, Sonoda S, Yock PG, Leon MB, Moses JW, Bonneau HN, Fitzgerald PJ. Late incomplete stent apposition after sirolimus-eluting stent implantation:A serial intravascular ultrasound analysis. J Am Coll Cardiol. 2005;46:1002-1005
47. Hong MK, Mintz GS, Lee CW, Park DW, Park KM, Lee BK, Kim YH, Song JM, Han KH, Kang DH, Cheong SS, Song JK, Kim JJ, Park SW, Park SJ. Late stent malapposition after drug-eluting stent implantation:An intravascular ultrasound analysis with long-term follow-up. Circulation.2006;113:414-419
48. Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A, Guagliumi G, Wijns W, Lindeboom WK, Ligthart J, de Feyter PJ, Morice MC. Intravascular ultrasound findings in the multicenter, randomized, double-blind ravel (randomized study with the sirolimus-eluting velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions) trial. Circulation. 2002;106:798-803
49. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier B, Windecker S. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation.2007;115:2426-2434
50. Hassan AK, Bergheanu SC, Stijnen T, van der Hoeven BL, Snoep JD, Plevier JW, Schalij MJ, Wouter Jukema J. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J.2009;31:1172-1180
51. Gonzalo N, Barlis P, Serruys PW, Garcia-Garcia HM, Onuma Y, Ligthart J, Regar E. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for st-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina:Insights from optical coherence tomography. JACC Cardiovasc Interv.2009;2:445-452
52. Kubo T, Imanishi T, Kitabata H, Kuroi A, Ueno S, Yamano T, Tanimoto T, Matsuo Y, Masho T, Takarada S, Tanaka A, Nakamura N, Mizukoshi M, Tomobuchi Y, Akasaka T. Comparison of vascular response after sirolimus-eluting stent implantation between patients with unstable and stable angina pectoris:A serial optical coherence tomography study. JACC Cardiovasc Imaging.2008; 1:475-484
53. Ozaki Y, Okumura M, Ismail TF, Naruse H, Hattori K, Kan S, Ishikawa M, Kawai T, Takagi Y, Ishii J, Prati F, Serruys PW. The fate of incomplete stent apposition with drug-eluting stents:An optical coherence tomography-based natural history study. Eur Heart J.2010;31:1470-1476
54. Lee CW, Kang SJ, Park DW, Lee SH, Kim YH, Kim JJ, Park SW, Mintz GS, Park SJ. Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation. J Am Coll Cardiol. 2010;55:1936-1942
55. Nakazawa G, Vorpahl M, Finn AV, Narula J, Virmani R. One step forward and two steps back with drug-eluting-stents:From preventing restenosis to causing late thrombosis and nouveau atherosclerosis. JACC Cardiovasc Imaging. 2009;2:625-628
56. Popma JJ, Tiroch K, Almonacid A, Cohen S, Kandzari DE, Leon MB. A qualitative and quantitative angiographic analysis of stent fracture late following sirolimus-eluting stent implantation. Am J Cardiol.2009; 103:923-929
57. Aoki J, Nakazawa G, Tanabe K, Hoye A, Yamamoto H, Nakayama T, Onuma Y, Higashikuni Y, Otsuki S, Yagishita A, Yachi S, Nakajima H, Hara K. Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv.2007;69:380-386
58. Lee SH, Park JS, Shin DG, Kim YJ, Hong GR, Kim W, Shim BS. Frequency of stent fracture as a cause of coronary restenosis after sirolimus-eluting stent implantation. Am J Cardiol.2007; 100:627-630
59. Ito T, Terashima M, Kaneda H, Nasu K, Kinoshita Y, Habara M, Tsuchikane E, Suzuki T. Very late sirolimus-eluting stent thrombosis due to stent fracture and late-acquired incomplete stent apposition detected on multislice computed tomography. Circ J.2011;75:2716-2717
60. Nakazawa G, Finn AV, Vorpahl M, Ladich E, Kutys R, Balazs I, Kolodgie FD, Virmani R. Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. J Am Coll Cardiol.2009;54:1924-1931
61. Doi H, Maehara A, Mintz GS, Tsujita K, Kubo T, Castellanos C, Liu J, Yang J, Oviedo C, Aoki J, Franklin-Bond T, Dasgupta N, Lansky AJ, Dangas GD, Stone GW, Moses JW, Mehran R, Leon MB. Classification and potential mechanisms of intravascular ultrasound patterns of stent fracture. Am J Cardiol.2009; 103:818-823
62. Hanna NN, Gaglia MA, Jr., Torguson R, Ben-Dor I, Gonzalez MA, Collins SD, Syed AI, Maluenda G, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R. Three-year outcomes following sirolimus-versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the rewards registry). Am J Cardiol.2010; 106:504-510
63. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333-342
64. Kim TH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK. Long-term (>/=2 years) follow-up optical coherence tomographic study after sirolimus-and paclitaxel-eluting stent implantation:Comparison to 9-month follow-up results. Int J Cardiovasc Imaging.2010;27:875-881
65. Murakami D, Takano M, Yamamoto M, Inami S, Ohba T, Seino Y, Mizuno K. Advanced neointimal growth is not associated with a low risk of in-stent thrombus. Optical coherence tomographic findings after first-generation drug-eluting stent implantation. Circ J.2009;73:1627-1634
66. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation.2002; 105:2974-2980
67. Ge L, Airoldi F, Iakovou I, Cosgrave J, Michev I, Sangiorgi GM, Montorfano M, Chieffo A, Carlino M, Corvaja N, Colombo A. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique:Importance of final kissing balloon post-dilation. J Am Coll Cardiol. 2005;46:613-620
68. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent:Should we be cautious? Circulation.2004; 109:701-705
69. Afergan E, Ben David M, Epstein H, Koroukhov N, Gilhar D, Rohekar K, Danenberg HD, Golomb G. Liposomal simvastatin attenuates neointimal hyperplasia in rats. AAPS J.2010;12:181-187
70. Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T, Onishi T, Iida O, Sera F, Nanto S, Hori M, Nagata S. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation:Comparison with bare-metal stents. Circulation.2007; 116:910-916
71. Takano M, Yamamoto M, Xie Y, Murakami D, Inami S, Okamatsu K, Seimiya K, Ohba T, Seino Y, Mizuno K. Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angioscopy. Heart.2007;93:1533-1536
72. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus-or paclitaxel-eluting stents. Circulation.2005; 112:270-278
73. Rogers C, Parikh S, Seifert P, Edelman ER. Endogenous cell seeding. Remnant endothelium after stenting enhances vascular repair. Circulation.1996;94:2909-2914
74. Drachman DE, Edelman ER, Seifert P, Groothuis AR, Bornstein DA, Kamath KR, Palasis M, Yang D, Nott SH, Rogers C. Neointimal thickening after stent delivery of paclitaxel:Change in composition and arrest of growth over six months. J Am Coll Cardiol.2000;36:2325-2332
75. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation.2001; 104:1188-1193
76. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents:Are human and animal studies comparable? Heart.2003;89:133-138
77. Parry TJ, Brosius R, Thyagarajan R, Carter D, Argentieri D, Falotico R, Siekierka J. Drug-eluting stents:Sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol.2005;524:19-29
78. Marks AR. Rapamycin:Signaling in vascular smooth muscle. Transplant Proc. 2003;35:231S-233S
79. Fukuda D, Sata M, Tanaka K, Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation.2005; 111:926-931
80. Jaschke B, Michaelis C, Milz S, Vogeser M, Mund T, Hengst L, Kastrati A, Schomig A, Wessely R. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res.2005;68:483-492
81. Tanner FC, Boehm M, Akyurek LM, San H, Yang ZY, Tashiro J, Nabel GJ, Nabel EG. Differential effects of the cyclin-dependent kinase inhibitors p27(kipl), p21(cip1), and pl6(ink4) on vascular smooth muscle cell proliferation. Circulation. 2000; 101:2022-2025
82. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabbani LE. Role for p27(kipl) in vascular smooth muscle cell migration. Circulation.2001; 103:2967-2972
83. Vinals F, Chambard JC, Pouyssegur J. P70 s6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. J Biol Chem. 1999;274:26776-26782
84. Hwang CW, Levin AD, Jonas M, Li PH, Edelman ER. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation.2005; 111:1619-1626
85. Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H, Neumann FJ. Inflammation and long-term mortality after non-st elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation.2002;105:1412-1415
86. Kim BK, Kim JS, Oh C, Ko YG, Choi D, Jang Y, Hong MK. Impact of preprocedural high-sensitivity c-reactive protein levels on uncovered stent struts:An optical coherence tomography study after drug-eluting stent implantation. Clin Cardiol. 2011;34:97-101
87. Park DW, Lee CW, Yun SC, Kim YH, Hong MK, Kim JJ, Park SW, Park SJ. Prognostic impact of preprocedural c reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. Heart.2007;93:1087-1092